ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION11:00 – 12:30 ED02: Palliative Care in Lung Cancer: A Global 11:00 – 12:30 SC02: Multifocal Lung Cancer Challenge TRACK: PULMONOLOGY TRACK: PALLIATIVE CARE/ETHICS ROOM: STRAUSS 1 ROOM: STRAUSS 3 CHAIRS: GIULIANA VERONESI, HUMANITAS RESEARCH CHAIRS: JEFFREY CRAWFORD, DUKE CANCER INSTITUTE, USA HOSPITAL, ITALY & SAULUS CICENAS, NATIONAL & JEAN , INSTITUT JULES BORDET, BELGIUM CANCER INSTITUTE, ITALY11:00 ED02.01: Palliative Care and its Importance for Patients 11:00 SC02.01: Multiple Primary Lung Cancers Versus Lung with Lung Cancer Metastases: Pathological Differential Diagnosis Herbert Watzke, Medical University of Vienna, Austria Erik Thunnissen, VU University Medical Center, Netherlands11:20 ED02.02: Palliative Care in South America 11:20 SC02.02: Surgical Choices for Patients with Multifocal Luis Alberto Mas Lopez, Instituto Nacional de Lung Cancer Enfermedades Neoplásicas, Peru Scott Swanson, Brigham and Women’s Hospital, USA11:40 ED02.03: Palliative Care in India 11:40 SC02.03: Surgery for Ground Glass Opacity: Sublobar Gouri Shankar Bhattacharyya, Fortis Hospital, Resection? Anandapur, India Shun–ichi Watanabe, National Cancer Center Hospital, Japan12:00 ED02.04: Palliative Care in South–East Asia Richard Lim, Selayang Hospital, Malaysia 12:00 SC02.04: Interactive Presentation of Clinical Cases with MONDAY DECEMBER 5 Multifocal Lung Cancer12:20 ED02.05: Palliative Care in Iran Alper Toker, Istanbul University Istanbul Medical School, Reza Malayeri, Firoozgar Hospital, Iran Turkey11:00 – 12:30 SC01: Staging Before and After Induction 11:00 – 12:30 SC03: Advances in Radiation Oncology Therapy for N2 Disease TRACK: RADIOTHERAPY TRACK: RADIOLOGY/STAGING/SCREENING ROOM: STRAUSS 2 CHAIRS: RICHARD PÖTTER, VIENNA GENERAL HOSPITAL, ROOM: LEHAR 3–4 AUSTRIA & HAK CHOY, UT SOUTHWESTERN MEDICAL CHAIRS: BERNWARD PASSLICK, UNIVERSITY OF CENTER, USA FREIBURG, GERMANY & GERHARD MOSTBECK, WILHELMINENSPITAL AND OTTO WAGNER HOSPITAL, AUSTRIA11:00 SC01.01: The Importance of Mediastinal Down–Staging 11:00 SC03.01: Advances in Stereotactic Body Radiotherapy During Induction Therapy of N2 Disease Matthias Guckenberger, University Hospital Zurich Paul De Leyn, University Hospital Leuven, Belgium (UniversitätsSpital Zürich), Switzerland11:20 SC01.02: PET–CT for Response Assessment During 11:20 SC03.02: Proton Therapy of Lung Cancer Induction Therapy of N2 NSCLC Jeffrey Bradley, Washington University School of Christoph Pöttgen, West German Cancer Center, Medicine, USA University of Duisburg–Essen, Germany 11:40 SC03.03: Carbon–Ion Therapy of Lung Cancer11:35 SC01.03: EBUS/EUS for Staging During Induction Yuko Nakayama, Kanagawa Cancer Center, Japan Therapy of N2 NSCLC Franz Stanzel, Institution, Germany 11:55 SC03.04: Molecular Predictive Biomarkers for Radiotherapy Outcome in Lung Cancer11:50 SC01.04: The Role of Mediastinoscopy in Induction Walter Curran, Winship Cancer Institute, USA Therapy of N2 NCSLC Sergi Call, Hospital Universitari MútuaTerrassa, Spain 12:10 SC03.05: Radiotherapy Combined with Targeted Therapies or Immunotherapy12:05 SC01.05: Video–Thoracoscopy for Staging of N2 NSCLC Rafal Dziadziuszko, Medical University of Gdansk, During Induction Therapy Poland Thomas D’Amico, Duke Cancer Institute, USA12:20 Q&A WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 99
11:00 – 12:30 SC04: EGFR Tyrosine Kinase Inhibitors: 11:00 – 12:30 IA01: Multidisciplinary Diagnosis of Lung A Model for Successful Drug Development Cancer in the Era of Molecular Medicine TRACK: CHEMOTHERAPY/TARGETED THERAPY/ ROOM: STOLZ 1 IMMUNOTHERAPY CHAIRS: KWUN FONG, THE PRINCE CHARLES HOSPITAL/ ROOM: HALL C7 UNIVERSITY OF QUEENSLAND, AUSTRALIA & ALES RYSKA, CHARLES UNIVERSITY MEDICAL FACULTY CHAIRS: SUMITRA THONGPRASERT, BANGKOK CHIANGMAI AND UNIVERSITY HOSPITAL, CZECH REPUBLIC HOSPITAL, THAILAND & OLIVER GAUTSCHI, LUZERNENER KANTONSSPITAL, SWITZERLAND 11:00 IA01.01: The Role Pathology for Diagnosis and Treatment of Lung Cancer 11:00 SC04.01: First– and Second Generation EGFR Tyrosine Helmut Popper, Medical University Graz, Austria Kinase Inhibitors James Chih–Hsin Yang, National Taiwan University and 11:20 IA01.02: What Endoscopic Techniques can Contribute NTU Cancer Center, Taiwan for Specimen Acquisition Arschang Valipour, Otto-Wagner-Spital, Austria 11:20 SC04.02: Management of Resistance to EGFR Tyrosine Kinase Inhibitors Tetsuya Mitsudomi, Kindai University Faculty of 11:40 IA01.03: What Every Lung Pathologist Needs to Know Medicine, Japan About Thoracic Surgery Hans Hoffmann, Thoraxklinik, University of Heidelberg, 11:40 SC04.03: Sequencing of EGFR Tyrosine Kinase Inhibitors Germany Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, South Korea 12:00 IA01.04: Does Cytological Material Fit All – Lessons from EBUS/Bronchoscopy 12:00 SC04.04: Liquid Biopsies for Dynamic Monitoring of Wlodzimierz Olszewski, Institute of Oncology, Poland EGFR Mutations in Lung Cancer Martin Schuler, University Hospital Essen, Germany 12:20 Q&A 11:00 – 12:30 IA02: Interactive Session Staging Group I (Ticketed Session)MONDAY DECEMBER 5 11:00 – 12:30 SC05: Novel Drugs in Thoracic Cancers TRACK: RADIOLOGY/STAGING/SCREENING TRACK: CHEMOTHERAPY/TARGETED THERAPY/ ROOM: SCHUBERT 3 IMMUNOTHERAPY COORDINATORS: KARIN DIECKMANN, AUSTRIA ROOM: HALL C2 & HELMUT PROSCH, AUSTRIA CHAIRS: ROY HERBST, YALE SCHOOL OF MEDICINE & 11:00 IA02.01: Interactive Session Staging NAGAHIRO SAIJO, JAPANESE SOCIETY MEDICAL Libor Havel, Czech Republic, Anna Kerpel-Fronius, ONCOLOGY Hungary & Elisabeth Stiefsohn, Austria 11:00 SC05.01: Immunotherapy in Malignant Pleural *Please note that this session is a duplicate of the Mesothelioma session on Tuesday Raffit Hassan, National Cancer Institute, USA 11:20 SC05.02: Novel Cytotoxic Drugs in Lung Cancer 11:00 – 12:30 NU01: Prevention Jean–Charles Soria, Gustave Roussy, France TRACK: NURSES 11:40 SC05.03: Novel Tyrosine Kinase Inhibitors in Lung ROOM: SCHUBERT 5 Cancer CHAIRS: LIZ DARLISON, UNIVERSITY HOSPITAL LEICESTER, UK Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China & IVETA NOHAVOVA, CHARLES UNIVERSITY PRAGUE, CZECH REPUBLIC 12:00 SC05.04: Lung Cancer Vaccines: An Update Elisabeth Quoix, Hôpitaux universitaires de Strasbourg Nouvel Hôpital Civil, France 11:00 NU01.01: China at the Crossroads: Findings from the ITC China Project on the Current State of Tobacco Control in 12:20 Q&A China Geoffrey Fong, University of Waterloo, Canada 11:20 NU01.02: Global View of Smoking Cessation Stella Bialous, UCSF School of Nursing, USA 11:40 NU01.03: The Role of Oncology Nurses & Smoking Cessation Iveta Nohavova, Charles University Prague, Czech Republic 12:00 NU01.04: Stigma in Lung Cancer Janine Cataldo, University of California, San Francisco, USA 100 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION12:15 NU01.05: Indigenous Population with Lung Cancer 11:20 OA01.03: Impact of Increasing Age on Cause–Specific Gail Garvey, Menzies School of Health Research, Mortality and Morbidity in Stage I NSCLC Patients: Australia A Competing Risk Analysis Takashi Eguchi, Memorial Sloan Kettering Cancer Center, USA11:00 – 12:30 PA01: Lung Cancer Diagnosis and Care: 11:30 OA01.04: Discussant Identifying and Improving Community Alessandro Brunelli, St. James’s University Hospital, UK Standards 11:45 OA01.05: The Impact of Lung Age on Postoperative Complications in Patients with Lung Cancer Combined TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS with Pulmonary Fibrosis and Emphysema Masahito Naito, Kitasato University School of Medicine, ROOM: SCHUBERT 6 Japan CHAIRS: BONNIE J. ADDARIO, BONNIE J. ADDARIO LUNG 11:55 OA01.06: Early Post–Operative Ambulation after CANCER FOUNDATION, USA & BLAZ BAJEC, CANCER Thoracic Surgery – The WAVE Experience PATIENTS’ ASSOCIATION OF SLOVENIA, SLOVENIA Sandeep Khandhar, CVTSA, USA11:00 PA01.01: The Importance of Patient Access to Molecular Testing and Novel Therapies Janet Freeman–Daily, #LCSM Chat (LCSM = Lung Cancer 12:05 OA01.07: Alternative Follow–Up Methods Based on Social Media), USA Recurrence Patterns after Surgery for Non–Small Cell Lung Cancer11:20 PA01.02: The Route to Diagnosis: Impacting Survival by Katsuya Watanabe, Yokohama Medical Center, Japan MONDAY DECEMBER 5 Changing the System Thomas Newsom–Davis, Chelsea and Westminster NHS 12:15 OA01.08: Discussant Foundation Trust, UK Thomas Klikovits, Medical University Vienna, Austria11:40 PA01.03: Establishing a Paradigm for High Quality Lung Cancer Treatment David Leduc, Addario Lung Cancer Foundation, USA 11:00 – 12:30 OA02: Novel Targets and Biomarkers in Malignant Pleural Mesothelioma12:00 PA01.04: Nurse–Led Lung Cancer Support Service Claire Mulvihill, Lung Foundation Australia, Australia TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC12:15 PA01.05: Lung Cancer Management in Turkey MALIGNANCIES Seda Kansu, Pembe Hanim, Turkey ROOM: STOLZ 2 CHAIRS: LUIS E. RAEZ, MEMORIAL CANCER INSTITUTE, USA & MARKO JAKOPOVICH, UNIVERSITY HOSPITAL CENTRE ZAGREB, CROATIA11:00 – 12:30 OA01: Risk Assessment and Follow up in 11:00 OA02.01: The microRNA–15/16 Family Regulates Tumour Surgical Patients Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma TRACK: SURGERY Karin Schelch, Asbestos Diseases Research Institute, Australia ROOM: SCHUBERT 2, LEVEL ONE 11:10 OA02.02: Gremlin–1 is a Key Regulator of the Invasive CHAIRS: WEN–ZHAO ZHONG, GUANGDONG GENERAL Phenotype in Mesothelioma HOSPITAL & GUANGDONG ACADEMY OF MEDICAL Katri Koli, University of Helsinki, Finland SCIENCES, CHINA & ERIC LIM, ROYAL BROMPTON HOSPITAL, UK11:00 OA01.01: Institutional–Based Differences in the Quality and Outcomes of US Lung Cancer Resections Raymond Osarogiagbon, Baptist Cancer Center, USA 11:20 OA02.03: Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients –11:10 OA01.02: A Lung Cancer Surgical Mortality Risk– A Multi–Institutional Study Prediction Algorithm to Inform Lung Cancer Screening Yawen Dong, Medical University Vienna, Austria Shared Decision–Making Joshua Roth, Fred Hutchinson Cancer Research Center, 11:30 OA02.04: Discussant USA Michaela Kirschner, University Hospital Zurich, Switzerland WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 101
11:45 OA02.05: Expression of miR–223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumour Microenvironment 11:00 – 12:30 OA04: Epidemiology and Prevention of Lung Kadir Sarun, Asbestos Diseases Research Institute, Cancer Australia TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND 11:55 OA02.06: Converting Tumor–Mediated PD–L1 Inhibition CESSATION/PREVENTION into CAR T–Cell Costimulation to Potentiate Thoracic Cancers Immunotherapy ROOM: SCHUBERT 4 Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, USA CHAIRS: LUBOŠ PETRUZELKA, CHARLES UNIVERSITY, CZECH REPUBLIC & SURENDRA SHASTRI, TATA MEMORIAL CENTER, INDIA 11:00 OA04.01: Educational and Wealth Inequalities in Tobacco Use among Men and Women in 54 Low–And– 12:05 OA02.07: Characterization of the Tumor Middle–Income Countries Microenvironment and Investigation of Immune Chandrashekhar Sreeramareddy, International Medical Checkpoint Expression in Malignant Pleural University, Malaysia Mesothelioma Elly Marcq, University of Antwerp, Belgium 11:10 OA04.02: Smoking Behavior in Patients with Early Stage Non–Small Cell Lung Cancer: A Report from ECOG– 12:15 OA02.08: Discussant ACRIN 1505 Trial Michael Grusch, Medical University Vienna, Austria Suresh Ramalingam, Winship Cancer Institute of Emory University, USA 11:20 OA04.03: Preliminary Results of a Low Cost Intervention to Improve Tobacco Cessation Practices 11:00 – 12:30 OA03: Immunotheraphy Checkpoint within a Large University Health System Inhibitors in Advanced NSCLC Douglas Arenberg, University of Michigan, USA TRACK: CHEMOTHERAPY/TARGETED THERAPY/ 11:30 OA04.04: Discussant IMMUNOTHERAPY Gilberto Lopes, HCor Onco, Oncoclinicas do Brasil and Johns Hopkins University, Brazil ROOM: HALL C8 CHAIR: LUCIO CRINÒ, PERUGIA HOSPITAL, ITALYMONDAY DECEMBER 5 11:00 OA03.01: First–Line Nivolumab Monotherapy and 11:45 OA04.05: Chronic Inflammation, NSAIDS and the Risk of Nivolumab plus Ipilimumab in Patients with Advanced Lung Cancer Death NSCLC: Long–Term Outcomes from CheckMate 012 Marisa Bittoni, The Ohio State University, USA Scott Gettinger, Yale Cancer Center, USA 11:55 OA04.06: Examining Pleiotropic Associations of Genetic Risk Variants for Chronic Obstructive Pulmonary 11:10 OA03.02: Atezolizumab as 1L Therapy for Advanced Disease with Lung Cancer Risk NSCLC in PD–L1–Selected Patients: Updated ORR, PFS Lori Sakoda, Kaiser Permanente Northern California, USA and OS Data from the BIRCH Study Marina Garassino, Fondazione IRCCS Istituto Nazionale 12:05 OA04.07: Clinical Characteristics of Lung dei Tumori, Italy Adenocarcinoma in the Young: Results from the Genomics of Young Lung Cancer Study 11:20 OA03.03: JAVELIN Solid Tumor: Safety and Clinical Barbara Gitlitz, University of Southern California Keck Activity of Avelumab (Anti–PD–L1) as First–Line School of Medicine, USA Treatment in Patients with Advanced NSCLC Claire Verschraegen, University of Vermont Cancer 12:15 OA04.08: Discussant Center, USA Ruxandra Ulmeanu, Institutul Marius Nasta Bucureti, Romania 11:30 OA03.04: Discussant Edward Garon, UCLA Medical Center, USA 11:45 OA03.05: Analysis of Early Survival in Patients with Advanced Non–Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 11:00 – 12:30 MA01: Improvement and Implementation of Solange Peters, University of Lausanne, Switzerland Lung Cancer Screening 11:55 OA03.06: Evaluation of Toxicity Profile of PD–1 versus TRACK: RADIOLOGY/STAGING/SCREENING PD–L1 Inhibitors in Non–Small Cell Lung Cancer (NSCLC) ROOM: LEHAR 1–2 Rathi Pillai, Winship Cancer Institute, Emory University, CHAIRS: MICHAEL STUDNICKA, UNIVERSITY OF SALZBURG, USA AUSTRIA & TBA 12:05 OA03.07: KEYNOTE–010: Durable Clinical Benefit in 11:00 MA01.01: Detection of Lung Cancer and EGFR Mutations Patients with Previously Treated, PD–L1–Expressing by Electronic Nose System NSCLC Who Completed Pembrolizumab Nir Peled, Davidoff Cancer Center, Israel Roy Herbst, Yale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, USA 11:06 MA01.02: Non–Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with 12:15 OA03.08: Discussant Drugs Such as Iloprost Paul Mitchell, Austin Health, Australia Javier Zulueta, VisionGate, USA 102 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION11:12 MA01.03: The Non–Invasive LuCED® Test for Detection of Early Stage Lung Cancer Javier Zulueta, VisionGate, USA 12:45 – 14:15 ISS07: Immuno–Oncology and Lung Cancer: Emerging Data and Recent Developments11:18 MA01.04: Discussant – Bristol–Myers Squibb Jiri Votruba, Czech Republic TRACK: INDUSTRY SUPPORTED SYMPOSIUM11:30 MA01.05: Predictive Performances of NELSON Screening Program Based on Clinical, Metrological and ROOM: HALL D (PLENARY HALL) Population Statistics Hubert Beaumont, MEDIAN Technologies, France CHAIR: MATTHEW HELLMANN, MEMORIAL SLOAN KETTERING CANCER CENTER, USA 12:45 ISS07.01: Welcome & Introduction Matthew Hellmann, Memorial Sloan Kettering Cancer11:36 MA01.06: Long–Term Follow–Up of Small Pulmonary Center, USA Ground–Glass Nodules Stable for 3 Years: Proper Follow–Up Period and Risk Factors for Subsequent 12:55 ISS07.02: Developments in the Use of I–O Monotherapy Growth in Lung Cancers Choon–Taek Lee, Seoul National University Bundang Enriqueta Felip, Hospital Universitari Vall d’Hebron, Hospital, South Korea Spain11:42 MA01.07: Influence of Nodule Morphology on 13:10 ISS07.03: Rationale for Studying I–O Combo Therapies Inter–Reader Variability of Volume and Diameter to Address Unmet Needs in Lung Cancer Measurements in CT Lung Cancer Screening Matthew Hellmann, Memorial Sloan Kettering Cancer MONDAY DECEMBER 5 Marjolein Heuvelmans, University Medical Center Center, USA Groningen, UMCG, Center for Medical Imaging– North East Netherlands, Netherlands 13:35 ISS07.04: Clinical Lessons Learned for the Use of I–O Therapies11:48 MA01.08: Discussant Jürgen Wolf, Universitätsklinikum Köln, Germany Ricardo Santos, Instituto Tórax, Brazil 13:55 ISS07.05: Close & Outlook Matthew Hellmann, Memorial Sloan Kettering Cancer12:00 MA01.09: Mortality, Survival and Incidence Rates in Center, USA the ITALUNG Randomised Lung Cancer Screening Trial (ITALY) 14:00 Audience Q&A – Full Panel Eugenio Paci, Institute for Cancer Prevention and Research (ISPO), Italy12:06 MA01.10: Performance of ACR Lung–RADS in the 1st Brazilian Lung Cancer Screening Trial (BRELT1) Ricardo Santos, Hospital Israelita Albert Einstein, Brazil12:12 MA01.11: Implementation of LDCT Lung Cancer 14:20 – 15:50 OA05: Treatment Advances in SCLC Screening into Practice. Results of Regional Early Detection Program TRACK: SCLC/NEUROENDOCRINE TUMORS Maciej Bryl, Wielkopolskie Centrum Pulmonologii i ROOM: STRAUSS 2 Torakochirurgii, Poland CHAIRS: ANDREA ARDIZZONI, UNIVERSITY HOSPITAL, ITALY12:18 MA01.12: Discussant & JEAN–LOUIS PUJOL, ARNAUD DE VILLENEUVE David Yankelevitz, Icahn School of Medicine at Mount HOSPITAL, FRANCE Sinai, USA 14:20 OA05.01: Pembrolizumab in Patients with Extensive– Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE–028 Patrick Ott, Dana–Farber Cancer Institute, USA 14:30 OA05.02: Anti–Tumor Immunity is a Key Determinant of SCLC Survivorship Farhad Kosari, Mayo Clinic, USA 14:40 OA05.03: Single–Agent Rovalpituzumab Tesirine, a Delta–Like Protein 3 (DLL3)–Targeted Antibody–Drug Conjugate (ADC), in Small–Cell Lung Cancer (SCLC) David Spigel, Sarah Cannon Research Institute/ Tennessee Oncology, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 103
14:50 OA05.04: Discussant 14:20 – 15:50 OA07: Lymph Node Metastases and Other Leora Horn, Vanderbilt University Medical Center, USA Prognostic Factors for Local Spread 15:05 OA05.05: Randomized Phase 2 Study: Alisertib TRACK: SURGERY (MLN8237) or Placebo + Paclitaxel as Second–Line Therapy for Small–Cell Lung Cancer (SCLC) ROOM: STOLZ 1 Taofeek Owonikoko, Emory University, USA CHAIR: VITEZSLAV KOLEK, FAKULTNI NEMOCNICE 15:15 OA05.06: Compliance and Outcome of Elderly Patients OLOMOUC, CZECH REPUBLIC & TIBOR KRAJC, Treated in the Concurrent Once–Daily versus Twice– AUSTRIA Daily RadioTherapy (CONVERT) Trial 14:20 Marianna Christodoulou, The Christie NHS Foundation OA07.01: Incidence, Local Distribution and Impact of Trust, UK pN2 Skip Metastasis in Patients Undergoing Curative Resection for NSCLC Ariane Steindl, Medical University Vienna, Austria 15:25 OA05.07: Prognostic Value of Circulating Tumour Cells 14:30 OA07.02: Omitting Intrapulmonary Lymph Node in Limited–Disease Small Cell Lung Cancer Patients Retrieval May Affect the Oncological Outcome of Treated on the CONVERT Trial pN0 Lung Cancer Patients: A Propensity Score Match Fabiola Fernandez–Gutierrez, CRUK Manchester Analysis Institute, UK Nan Wu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China 15:35 OA05.08: Discussant Jens Benn Sørensen, Finsen Centre/National University Hospital, Denmark 14:40 OA07.03: Prognostic Significance of Micrometastases in Mediastinal Lymph Nodes of Patients With Radically Resected Non–Small Cell Lung Cancer Pawel Gwózdz, Pulmonary Hospital, Poland 14:20 – 15:50 OA06: Prognostic & Predictive Biomarkers 14:50 OA07.04: Discussant Yi Long Wu, Guangdong Lung Cancer Institute, China TRACK: BIOLOGY/PATHOLOGY ROOM: STRAUSS 1 15:05 OA07.05: Prognostic Impact of Pleural Lavage Cytology CHAIRS: FRANCES SHEPHERD, PRINCESS MARGART CANCER (PLC): Significance of PLC after Lung ResectionMONDAY DECEMBER 5 Shinya Katsumata, National Cancer Center Hospital CENTRE, CANADA & YASUSHI YATABE, AICHI CANCER East, Japan CENTER, JAPAN 15:15 OA07.06: In Early–Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor 14:20 OA06.01: Clinical Utility of Circulating Tumor DNA Spread through Air Spaces (ctDNA) Analysis by Digital next Generation Sequencing Takashi Eguchi, Memorial Sloan Kettering Cancer Center, of over 5,000 Advanced NSCLC Patients USA Philipp Mack, UC Davis Cancer Center, USA 14:30 OA06.02: Mutational Load Predicts Survival in LDCT 15:25 OA07.07: Discussant Screening–Detected Lung Cancers Mark Krasnik, Denmark Gabriella Sozzi, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Italy 14:40 OA06.03: Transcriptome Analysis of ATM–Deficient NSCLC Lars Petersen, University of Calgary, Canada 14:20 – 15:50 MA02: RNA in Lung Cancer 14:50 OA06.04: Discussant TRACK: BIOLOGY/PATHOLOGY Ross Soo, National University Health System, Singapore ROOM: STOLZ 2 CHAIRS: ELISABETH BRAMBILLA, INSTITUT ALBERT BONNIOT, 15:05 OA06.05: Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of HOPITAL ALBERT MICHALLON, FRANCE & MASAYUKI Samples from the TASTE Trial NOGUCHI, UNIVERSITY OF TSUKUBA, JAPAN Jean–Charles Soria, Gustave Roussy Cancer Campus and University Paris–Sud, France 14:20 MA02.01: Extracellular Vescicle miRNAs Regulate Gene Expression in Local Lung Adenocarcinoma Endothelial 15:15 OA06.06: Druggable Alterations Involving Crucial Cells Carcinogenesis Pathways Drive the Prognosis of James Lawson, BC Cancer Research Center, Canada Squamous Cell Lung Carcinoma (SqCLC) Sara Pilotto, University of Verona, Italy 14:26 MA02.02: A Novel 5–miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response 15:25 OA06.07: Evaluating Genomic Signatures Predicting in NSCLC Veliparib Sensitivity in Non–Small Cell Lung Cancer Martin Barr, St. James’s Hospital & Trinity College (NSCLC) Dublin, Ireland Lei He, AbbVie Inc., USA 14:32 MA02.03: Expression of Oncofetal miRNAs Inactivates NFIB, a Developmental Transcription Factor Linked to 15:35 OA06.08: Discussant Tumour Aggressiveness in Lung Adenocarcinoma Maya Gottfried, Meir Medical Center, Israel Daiana Becker–Santos, British Columbia Cancer Research Centre, Canada 104 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION14:38 MA02.04: Discussant 14:50 MA03.05: Cost Effectiveness Analysis of CT vs Chest Luis Montuenga, CIMA. University of Navarra, Spain X–Ray (CXR) vs No Screening for Lung Cancer (LC) in the PLCO and NLST Randomized Population Trials (RPTs)14:56 MA02.05: Distinct Angiogenic microRNA–mRNA John Paul Flores, Tufts Medical Center, USA Expression Profiles among Subtypes of Lung Adenocarcinoma 14:56 MA03.06: Cost Effectiveness of Chest Scan Screeing Mirella Giordano, University of Pisa, Italy for Lung Cancer in Abestos Occupational Exposure Subjects: A Model Based Study15:02 MA02.06: Discussant Christos Chouaid, GRC OncoEst Creteil, France Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, 15:02 MA03.07: Discussant Spain Thierry Berghmans, Institut Jules Bordet, Belgium15:14 MA02.07: Evaluation of Exosomal miRNAs from Plasma 15:14 MA03.08: Quantifying Survival in Early–Stage NSCLC: as Potential Biomarker for NSCLC Implications of Relative Survival vs Cause–Specific Xiance Jin, The 1st Affiliated Hospital of Wenzhou Survival Medical University, China Kay See Tan, Memorial Sloan Kettering Cancer Center, USA15:20 MA02.08: Deregulation of Cis–Acting Long Non–Coding 15:20 MA03.09: Retrospective Predictive Performance of RNAs in Non–Small Cell Lung Cancer a Lung Cancer Screening Risk Prediction Model in a Adam Sage, BC Cancer Research Centre, Canada Clinical Lung Cancer Screening Program Andrea Borondy Kitts, Lahey Hospital & Medical Center,15:26 MA02.09: Long Non–Coding RNA Expression from USA MONDAY DECEMBER 5 Pseudogene Loci as a Novel Mechanism of Cancer Gene Regulation 15:26 MA03.10: Educational Level and the Management and Greg Stewart, BC Cancer Research Centre, Canada Outcome in Non–Small Cell Lung Cancer: A Nationwide Study (Sweden)15:32 MA02.10: Discussant Anna Öjdahl Boden, Karolinska University Hospital Bojan Zaric, Serbia Huddinge, Sweden 15:33 MA03.11: Discussant Oleg Pikin, Hertzen Research Institute of Oncology,14:20 – 15:50 MA03: Epidemiology, Risk Factors and Russia Screening 14:30 – 15:15 JTO: Meet the JTO Editor TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION ROOM: SCHUBERT 4 CHAIRS: ALEX ADJEI, ROSWELL PARK CANCER INSTITUTE, USA ROOM: LEHAR 3–4 14:30 Meet the JTO Editor CHAIRS: NAZMI BILIR, HACETTEPE UNIVERSITY, TURKEY & Alex Adjei, Roswell Park Cancer Institute, USA HORST OLSCHEWSKI, MEDIZINISCHE UNIVERSITAET GRAZ, AUSTRIA14:20 MA03.01: Gender Disparities in Non–Small Cell Lung Cancer: A Systematic Review Gwyn Bebb, Alberta Health Services, Canada14:26 MA03.02: Lung Cancer in Women 1929 to 2016: Cold– Blooded Origins of an Epidemic Fred Grannis, City of Hope National Medical Center, USA 14:30 – 15:45 ED03: Global Tobacco Control Policies: Advances & Challenges14:32 MA03.03: High Risk for Second Primary Lung Cancer in Taiwanese Early–Onset Female Breast Cancer Patients TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND Pei–Ying Lin, National Taiwan University Hospital, CESSATION/PREVENTION Taiwan ROOM: HALL C114:38 MA03.04: Discussant Ana Jovicevic, Institute for Oncology and Radiology of CHAIRS: GABOR KOVÁCS, OKTPI, HUNGARY & XIUYI ZHI, Serbia, Russia XUANWU HOSPITAL, CAPITAL MEDICAL UNIVERSITY, CHINA 14:30 ED03.01: Tobacco Control in the Middle East Feras Hawari, The King Hussein Cancer Foundation, Jordan WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 105
14:50 ED03.02: The Australian Tobacco Control Strategy: Lessons Learned Mike Daube, Curtin University, Australia 14:30 – 15:45 IA03: Interactive Session: What are the Lung Cancer Patients Needs in the Different 15:10 ED03.03: Tobacco Control and Lung Cancer in Africa Countries? Lekan Ayo-Yusuf, Sefako Makgatho Health Sciences University, South Africa TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS (INTERACTIVE SESSION) 15:30 ED03.04: Trumping Big Tobacco Bronwyn King, Tobacco Free Portfolios, Australia ROOM: SCHUBERT 2, LEVEL ONE CHAIRS: STEFANIA VALLONE, ITALY, INGEBORG BEUNDERS, AUSTRIA & NELLY ENWEREM-BROMSON, IAEA/PACT, AUSTRIA 14:30 – 15:45 ED04: Bronchopulmonary Carcinoids Patient needs around the world. Participants will place notes showing the needs in the countries on a map, TRACK: SCLC/NEUROENDOCRINE TUMORS which will be followed by a discussion. Outcome of the ROOM: LEHAR 1–2 interactive session will be presented at the end of the CHAIRS: VERA GORBUNOVA, N.N. BLOKHIN RUSSIAN CANCER Conference by Stefania Vallone and Ingeborg Beunders. RESEARCH CENTER, RUSSIA & JOERG HUTTER, SALK INTERNATIONAL, AUSTRIA 14:30 ED04.01: Surgery in Bronchopulmonary Typical and 14:30 – 15:45 PC01: Pro Con Session: Atypical Carcinoids Invasive Mediastinal Staging for N2 Disease Pier Luigi Filosso, University of Torino, Italy TRACK: RADIOLOGY/STAGING/SCREENING, LOCALLY 15:00 ED04.02: Systemic Therapy of Bronchopulmonary ADVANCED NSCLC Typical and Atypical Carcinoids: Current Status and Perspectives ROOM: HALL C2 Eric Baudin, Gustave–Roussy Cancer Campus, France CHAIRS: WALTER WEDER, UNIVERSITY HOSPITAL ZURICH, SWITZERLAND & HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIAMONDAY DECEMBER 5 14:30 PC01.01: Introduction & Vote Helmut Prosch, Medical University of Vienna, Austria 14:30 – 15:45 SC06: Novel Therapies in Malignant Pleural 14:40 PC01.02: Invasive Staging and Restaging Mesothelioma and Thymic Malignancies Christophe Dooms, University Hospitals KU Leuven, Belgium TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC 15:00 PC01.03: No Invasive Staging Nor Restaging MALIGNANCIES Eric Lim, UK ROOM: STRAUSS 3 15:20 PC01.04: Discussion & Vote Walter Weder, University Hospital Zurich, Switzerland CHAIRS: ANNA NOWAK, UNIVERSITY OF WESTERN AUSTRALIA, AUSTRALIA & TAKASHI NAKANO, HYOGO COLLEGE OF MEDICINE, JAPAN 14:30 SC06.01: Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma Raphael Bueno, Brigham and Women’s Hospital, USA 14:30 – 15:45 Poster Presenters Present 14:50 SC06.02: Stratified Therapy for Malignant Pleural for P1 Posters Mesothelioma Dean Fennel, UK ROOM: HALL B (EXHIBIT HALL) 15:10 SC06.03: Intraoperative Therapies in Malignant Pleural P1.01 Epidemiology/Tobacco Control and Cessation/ Mesothelioma Prevention Isabelle Opitz, University Hospital Zurich, Switzerland P1.02 Biology/Pathology 15:30 SC06.04: Immunotherapy of Malignant Pleural P1.03 Radiology/Staging/Screening Mesothelioma and Thymic Malignancies: The End of the P1.04 Pulmonology Beginning? P1.05 Early Stage NSCLC Jan Van Meerbeeck, Antwerp University Hospital, P1.06 Advanced NSCLC & Chemotherapy/Targeted Therapy/ Belgium Immunotherapy P1.07 SCLC/Neuroendocrine Tumors P1.08 Surgery 106 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION16:00 – 17:30 ED05: The 8th Edition of the TNM Staging 16:00 – 17:30 SC07: New Challenges for Lung Cancer: System Waterpipes and E–Cigarettes TRACK: RADIOLOGY/STAGING/SCREENING TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION ROOM: HALL C1 ROOM: STOLZ 2 CHAIRS: PETER GOLDSTRAW, NATIONAL HEART AND LUNG INSTITUTE, IMPERIAL COLLEGE, UK & RAMON RAMI– CHAIRS: MARTINA PÖTSCHKE–LANGER, GERMAN CANCER PORTA, HOSPITAL UNIVERSITARI MUTUA TERRASSA, RESEARCH CENTER, GEMRANY & MANFRED AND CIBERES LUNG CANCER GROUP, SPAIN NEUBERGER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIAN ACADEMY OF SCIENCE, AUSTRIA16:00 ED05.01: What’s New in Lung Cancer Staging? 16:00 SC07.01: Carcinogen Exposure from Waterpipe and Hisao Asamura, Keio University School of Medicine, ENDS (Electronic Nicotine Delivery Devises) Japan Alan Shihadeh, American University of Beirut, Lebanon16:25 ED05.02: Update on the Mesothelioma Staging System 16:25 SC07.02: Health Effects of E–Cigarette Aerosol and Valerie Rusch, Memorial Sloan–Kettering Cancer Center, Nicotine Exposure on the Respiratory System USA Charlotta Pisinger, Glostrup Hospital, Denmark16:45 ED05.03: The Thymic Epithelial Tumor Staging System 16:50 SC07.03: Connections of Nicotine to Cancer and Its Kazuya Kondo, Tokushima University Graduate School, Influence on Cancer Treatment Japan Sergei Grando, University of California, USA MONDAY DECEMBER 517:05 ED05.04: What’s New in Esophageal Cancer Staging? 17:15 Q&A Thomas Rice, Cleveland Clinic, USA16:00 – 17:30 ED06: Symptom Management in Lung Cancer 16:00 – 17:30 SC08: IASLC– ESTS Joint Symposium: The Borderline Patient TRACK: PALLIATIVE CARE/ETHICS ROOM: STOLZ 1 TRACK: SURGERY CHAIRS: RICHARD GRALLA, ALBERT EINSTEIN COLLEGE OF ROOM: HALL C7 MEDICINE, USA, REZA MALAYERI, IRAN CHAIRS: JAROSLAW KUZDZAL, JAGIELLONIAN UNIVERSITY,16:00 ED06.01: Causes and Management of Dyspnea POLAND & HANS HOFFMANN, THORAXKLINIK, Otto Burghuber, Austria UNIVERSITÄTSKLINIKUM HEIDELBERG, GERMANY16:15 ED06.02: Endobronchial and Pleural Palliation 16:00 SC08.01: Impact and Management of Co–Morbidities Arschang Valipour, Otto Wagner Hospital, Austria Alessandro Brunelli, St. James’s University Hospital, UK 16:20 SC08.02: Emphysema as a Limiting Factor for Lung Resection: How Far We Can Go?16:30 ED06.03: Pain Management Walter Weder, University Hospital Zurich, Switzerland Vera Hirsh, McGill University, Royal Victoria Hospital, Canada 16:40 SC08.03: Surgical Issues in the Borderline Patient: Sublobar Versus Standard Resection16:45 ED06.04: Biology and Management of Tumor Cachexia David Harpole, Duke University, USA Jeffrey Crawford, Duke Cancer Institute, USA17:00 ED06.05: Surgery for Symptom Relief 17:00 SC08.04: SABR Versus Surgery Shahrokh Taghavi, Austria Norihiko Ikeda, Tokyo Medical University, Japan17:15 ED06.06: Decisions in Case of Intractable Symptoms 17:20 Q&A Jean Klastersky, Institut Jules Bordet, Belgium WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 107
16:20 SC11.02: Resistance to ALK Inhibitor Therapy Sai–Hong Ou, Chao Family Comprehensive Cancer 16:00 – 17:30 SC09: Radiotherapy for a Global Cancer Center, University of California Irvine School of Medicine, USA TRACK: RADIOTHERAPY ROOM: HALL C8 16:40 SC11.03: ROS1 as a Therapeutic Target in Advanced CHAIRS: YUKO NAKAYAMA, KANAGAWA CANCER CENTER, NSCLC Jürgen Wolf, University Hospital of Cologne, Germany JAPAN & DENIZ YALMAN, EGE UNIVERSITY, TURKEY 16:00 SC09.01: Global Access To Radiotherapy: Are We There? 17:00 SC11.04: Rare Mutations in Lung Cancer David Palma, London Health Sciences Centre, Canada Oliver Gautschi, Lucerne Cantonal Hospital, Switzerland 16:20 SC09.02: The Quest for High Quality Affordable 17:20 Q&A Radiotherapy in Developing Countries Hak Choy, UT Southwestern Medical Center, USA 16:40 SC09.03: Machine Learning for Individualized Radiotherapy Prescription Phillippe Lambin, Maastricht University, Netherlands 16:00 – 17:30 SC12: Anticancer Drug Development in the 21st Century 17:00 SC09.04: Radiotherapy in China Luhua Wang, Cancer Hospital, Chinese Academy of TRACK: CHEMOTHERAPY/TARGETED THERAPY/ Medical Sciences, China IMMUNOTHERAPY 17:20 Q&A ROOM: HALL C2 CHAIRS: LAWRENCE EINHORN, INDIANA UNIVERSITY, USA & KAORU KUBOTA, THORACIC ONCOLOGY RESEARCH GROUP, JAPAN 16:00 SC12.01: Establishment of EGFR Tyrosine Kinase Inhibitors: History and Lessons Learned for Future DrugMONDAY DECEMBER 5 16:00 – 17:30 SC10: Squamous Cell NSCLC Development Tony Mok, The Chinese University of Hong Kong, Hong TRACK: CHEMOTHERAPY/TARGETED THERAPY/ Kong IMMUNOTHERAPY 16:25 SC12.02: Molecular–Based Therapy of Lung Cancer: The ROOM: STRAUSS 3 Way Forward? Charles Rudin, Memorial Sloan Kettering Cancer Center, CHAIRS: DAVID R. GANDARA, UC DAVIS COMPREHENSIVE USA CANCER CENTER, USA & MARTIN, GOETHE UNIVERSITY, GERMANY 16:00 SC10.01: Genetic Alterations as Potential Therapeutic Targets Roman Thomas, Center for Integrated Oncology 16:45 SC12.03: Implications of Patient Selection: Are we Lost Cologne/Bonn, University of Cologne, Germany in Diversification? Yu Shyr, Vanderbilt University School of Medicine, USA 16:20 SC10.02: EGFR Mutations in Indian Patients with 17:05 SC12.04: Drug Development: The EMA Perspective Squamous Cell NSCLC Francesco Pignatti, European Medicines Agency, UK Kumar Prabhash, Tata Memorial Centre, India 17:25 Q&A 16:40 SC10.03: Anti–EGFR Monoclonal Antibodies in Squamous Cell NSCLC Robert Pirker, Medical University of Vienna, Austria 17:00 SC10.04: Second–Line Therapy and Beyond in Squamous 16:00 – 17:30 IA04: Interactive Session Target Delineation: Cell NSCLC Group I (Ticketed Session) Silvia Novello, University of Turin, Italy TRACK: RADIOTHERAPY 17:20 Q&A ROOM: SCHUBERT 3 COORDINATORS: KAREN DIECKMANN, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA 16:00 – 17:30 SC11: ALK, ROS1 and Rare Mutations in NSCLC 16:00 IA04.01: Interactive Session Target Delineation Trainers: Corinne Faivre-Finn, UK, Laurie Gaspar, USA, TRACK: CHEMOTHERAPY/TARGETED THERAPY/ Billy Loo, USA IMMUNOTHERAPY ROOM: CHAIR: LEHAR 1–2 DONG–WAN KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA 16:00 SC11.01: Optimal Application & Sequence of ALK Inhibition Therapy Benjamin Solomon, Peter MacCallum Cancer Centre, Australia 108 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION16:00 – 17:30 NU02: Preparing Patients for Treatment 16:00 – 17:30 OA08: Targeted Therapies in Brain Metastases TRACK: NURSES ROOM: SCHUBERT 5 TRACK: ADVANCED NSCLC CHAIRS: DIANA BORTHWICK, EDINBURGH CANCER CENTRE, ROOM: SCHUBERT 1, LEVEL ONE UK & ANNE FRASER, ADHB, NEW ZEALAND CHAIRS: DAVID BALL, PETER MACCALLUM CANCER CENTRE,16:00 NU02.01: Preparing Patients for Treatment. Providing AUSTRALIA & RAFAL DZIADZIUSZKO, MEDICAL Psychosocial Support for Lung Cancer Patients UNIVERSITY OF GDANSK, POLAND Preparing to Enter Treatment Andreja Cirila Škufca Smrdel, 1. Institute of Oncology 16:00 OA08.01: Exploration of the Underlying Mechanisms of Ljubljana, 2. Cancer Patients’ Association of Slovenia, Leptomeningeal Metastasis in NSCLC Patients through Slovenia NGS of Cerebrospinal Fluid Yun Fan, Zhejiang Cancer Hospital, China16:20 NU02.02: Preoperative Thoracic Surgery Patient 16:10 OA08.02: Phase II Study of Erlotinib in Advanced Non– Education Program Development Small Cell Lung Cancer Patients with Leptomeningeal Katherine Kuhns, Penn Presbyterian Medical Center, Metastasis (LOGIK1101) USA Keiichi Ota, Kyushu University, Japan16:40 NU02.03: Ethical Decision Making 16:20 OA08.03: MET Copy Number Gain Associates with Sabine Ruppert, Vienna General Hospital, Austria Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer17:00 NU02.04: Discussant Seiji Yano, Kanazawa University, Japan MONDAY DECEMBER 5 Harald Titzer, University Hospital of Vienna, Austria 16:30 OA08.04: Discussant Roman Perez–Soler, Montefiore Medical Center, USA 16:45 OA08.05: Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR16:00 – 17:30 PA02: Access to Care – Equal Chances Mutation Developing Leptomeningeal Carcinomatosis in the World? Akihiro Tamiya, Kinki–chuo Chest Medical Center, Japan TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS 16:55 OA08.06: Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical ROOM: SCHUBERT 6 Trials Scott Gettinger, Yale Cancer Center, USA CHAIRS: CHRISTINA VAN TZE NG, SUNWAY MEDICAL CENTER, MALAYSIA & SHANI SHILO, THE ISRAEL LUNG CANCER FOUNDATION, ISRAEL16:00 PA02.01: Access to Care: USA 17:05 OA08.07: BRAF–V600E Advanced Lung Adenocarcinoma Kim Norris, Lung Cancer Foundation of America, USA with Leptomeningeal (LM) Disease Treated with Vemurafenib16:15 PA02.02: Access to Care: South America Maria Gabriela Fernandes, Centro Hospitalar São João, Patricia Mondragon, Respirando Con Valor, Mexico Portugal16:30 PA02.03: Access to Care: Malaysia 17:15 OA08.08: Discussant Christina Van Tze Ng, The Cancer Advocacy Society of Niels Reinmuth, Hospital Grosshansdorf, Germany Malaysia, Malaysia16:45 PA02.04: Access to Care: Europe Szymon Chrostowski, Polish Cancer Patient Coalition, Poland17:00 PA02.05: Access to Care: Australia Kerrie Callaghan, Lung Foundation Australia, Australia17:15 PA02.06: Access to Care: Israel Shani Shilo, The Israel Lung Cancer Foundation, Israel WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 109
16:00 – 17:30 MA04: HER2, P53, KRAS and Other Targets 16:00 – 17:30 MA05: Innovative Techniques in in Advanced NSCLC Pulmonology and the Impact on Lung Cancer TRACK: ADVANCED NSCLC TRACK: PULMONOLOGY ROOM: LEHAR 3–4 ROOM: STRAUSS 1 CHAIRS: BAOHUI HAN, SHANGHAI CHEST HOSPITAL, CHAIRS: JOSEF ECKMAYR, AON, AUSTRIA & PRASANTA SHANGHAI JIAO TONG UNIVERSITY, CHINA & MOHAPATRA, ALL INDIA INSTITUTE OF MEDICAL WOLFGANG HILBE, AUSTRIA SCIENCES, INDIA 16:00 MA04.01: Non–Amplification Mutation of ERBB2 in 16:00 MA05.01: Virtual Bronchoscopic Navigation–Guided EGFR–Mutated Lung Cancer Ultrathin Bronchoscopy for Diagnosing Peripheral Jeffrey Ross, Albany Medical College, USA Pulmonary Lesions Marta Diez–Ferrer, Hospital Universitari de Bellvitge, 16:06 MA04.02: Neratinib ± Temsirolimus in HER2–Mutant Spain Lung Cancers: An International, Randomized Phase II Study 16:06 MA05.02: Electromagnetic Navigation Bronchoscopy: Leena Gandhi, Dana Farber Cancer Institute, USA A Prospective, Global, Multicenter Analysis of 1000 Subjects with Lung Lesions 16:12 MA04.03: Preliminary Results of a Phase II Study about Sandeep Khandhar, CVTSA/Inova Cancer Center, Fairfax the Efficacy and Safety of Pyrotinib in Patients with Hospital, USA HER2 Mutant Advanced NSCLC Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji 16:06 MA05.03: A Single EBUS–TBNA Pass Yields Sufficient University School of Medicine, Tongji University Cancer DNA for Targeted Molecular Testing in Lung Cancer Institute, China T racy Leong, The Walter and Eliza Hall Institute of Medical Research, Australia 16:18 MA04.04: Discussant Thanyanan Reungwetwattana, Ramathibodi Hospital, Thailand 16:18 MA05.04: Discussant Vitezslav Kolek, Fakultni Nemocnice Olomouc, Czech 16:30 MA04.05: P53 Non–Disruptive Mutation is a Negative Republic Predictive Factor for OS and PFS in EGFR M+ NSCLCMONDAY DECEMBER 5 Treated with TKI 16:30 MA05.05: Genomic Profiles of Lung Cancer Associated Frank Griesinger, Pius Hospital Oldenburg, Germany with Idiopathic Pulmonary Fibrosis Ji An Hwang, Asan Medical Center, South Korea 16:36 MA04.06: Signaling Networks in KRAS–Mutant 16:36 MA05.06: Diagnosis of Chronic Obstructive Pulmonary Advanced NSCLC: A Complex Landscape Involving Disease in Lung Cancer – A Population Based Study Immunoresponse, Inflammation and DNA Repair John Goffin, Juravinski Cancer Centre, Canada Sara Baglivo, Medical Oncology, Santa Maria della Misericordia Hospital, Italy 16:42 MA05.07: Identifying Comorbid Disease on Chest CT Scans in a Lung Cancer Screening–Eligible Cohort 16:42 MA04.07: Impact of Major Co–Mutations on the James Finigan, National Jewish Health, USA Immune Contexture and Response of KRAS–Mutant Lung Adenocarcinoma to Immunotherapy 16:48 MA05.08: Discussant Ferdinandos Skoulidis, The University of Texas M. D. Konstantinos Zarogoulidis, G. Papanikolaou Hospital, Anderson Cancer Center, USA Greece 16:48 MA04.08: Discussant 17:00 MA05.09: There is a Closely Relation between Exhaled Julian Molina, Mayo Clinic in Rochester, USA Nitric Oxide and Radiation Pneumonitis Jiancheng Li, Fujian Cancer Hospital, China 17:00 MA04.09: RICTOR Amplification in Non–Small Cell Lung 17:06 MA05.10: Cell–Free DNA Testing for EGFR Mutations in Cancer: An Emerging Therapy Target Clinical Practice – Facts and Figures from an Austrian Jeffrey Ross, Foundation Medicine, USA Lung Cancer Center David Lang, Kepler University Hospital, Austria 17:06 MA04.10: Lung Cancer Growth is Suppressed by CD26/ DPP4–Inhibition via Enhanced NK Cell and Macrophage Recruitment 17:12 MA05.11: Photodynamic Therapy for Peripheral Lung Jae–Hwi Jang, University Hospital Zürich, Switzerland Cancer Using Composite–Type Optical Fiberscope of 1.0 Mm in Diameter 17:12 MA04.11: Mechanistic Insights into CAR T–Cell Efficacy Jitsuo Usuda, Nippon Medical School, Japan in the Treatment of Heterogenous Antigen Expressing Lung Adenocarcinoma 17:18 MA05.12: Discussant Prasad Adusumilli, Memorial Sloan Kettering Cancer Judit Moldvay, National Koranyi Institute of Center, USA Pulmonology, Hungary 17:18 MA04.12: Discussant Ales Ryska, Fingerland Institute of Pathology, Czech Republic 110 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION 17:12 MA06.11: Phase II Study of Nimotuzumab + Concurrent Chemoradiotherapy (CRT) for Stage III Non–Small Cell16:00 – 17:30 MA06: Locally Advanced NSCLC: Risk Groups, Lung Cancer (NSCLC): 5–Year Follow–Up Results Biological Factors and Treatment Choices Kazushige Hayakawa, Kitasato University, Japan TRACK: LOCALLY ADVANCED NSCLC 17:18 MA06.12: Discussant Philip Bonomi, Rush University Medical Center, USA ROOM: STRAUSS 2 CHAIRS: PAUL VAN HOUTTE, INSTITUT JULES BORDET, BELGIUM & MILADA ZEMANOVÁ, 1ST FACULTY OF MEDICINE OF CHARLES UNIVERSITY IN PRAGUE, CZECH REPUBLIC16:00 MA06.01: Overall Survival Characterization of Incidental N2 Non–Small Cell Lung Cancer over 14 Years at a Single Canadian Institution 17:45 – 19:15 ISS08: Reaching New Heights in the Cara Van Der Merwe, University of Calgary, Canada Management of Non-Small Cell Lung Cancer: Focus on EGFR-Targeted Therapy – A prIME16:06 MA06.02: Does Pathological Staging Following Oncology satellite symposium supported by Neoadjuvant Therapy (ypTNM) Reflect the Reality? Boehringer Ingelheim Pharma GmbH & Co. KG Huseyin Melek, Uludag University, Turkey TRACK: INDUSTRY SUPPORTED SYMPOSIUM16:12 MA06.03: Recurrence Dynamics after Trimodality Therapy (Neoadjuvant Chemoradiotherapy and Surgery) ROOM: HALL C7 in Stage IIIa(N2) Lung Cancer MONDAY DECEMBER 5 Jung Hee Lee, Samsung Medical Center, Sungkyunkwan CHAIRS: MARTIN SCHULER, UNIVERSITY HOSPITAL ESSEN, University School of Medicine, South Korea GERMANY16:18 MA06.04: Discussant 17:45 ISS08.01: Welcome & Warm–up Quiz Fan Yang, Peking University People’s Hospital, China Martin Schuler, University Hospital Essen, Germany 17:50 ISS08.02: Key Decision Points for Personalized Patient Care of Advanced Non–Small Cell Lung Cancer (NSCLC) 16:30 MA06.05: Screening for Brain Metastases in Patients Martin Schuler, University Hospital Essen, Germany with Stage III NSCLC, MRI or CT? A Prospective Study Janna Schoenmaekers, MUMC, Netherlands 18:00 ISS08.03: Managing EGFR–Mutant Adenocarcinoma: What is the Optimal First–Line Approach? 16:36 MA06.06: Tumor Microenvironment and Brain Barbara Melosky, British Columbia Cancer Agency, Metastases in Completely Resected Stage IIIA(N2) Non– Canada Small Cell Lung Cancer Qin Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong 18:20 ISS08.04: Tackling Acquired Resistance to EGFR– University, China Targeted Therapy: Evaluating Current and Emerging Treatment Strategies 16:42 MA06.07: Impact of Type 2 Diabetes Mellitus and Its Keunchil Park, Samsung Med Ctr, Sungkyunkwan Univ Metabolic Control on Prognosis of Unresectable Non– School of Med, South Korea Small Cell Lung Cancer Patients Milana Bergamino Sirvén, Catalan Institut of Oncology 18:40 ISS08.05: Contemporary Management of Squamous – ICO Hospitalet, Spain Cell Carcinoma: What is the Role of EGFR–Targeted Therapy in the Era of Immunotherapy? 16:48 MA06.08: Discussant Marianne Nicolson, Aberdeen Royal Infirmary, UK Miroslaw Kozlowski, Medical University of Bialystok, Poland 18:55 ISS08.06: Quiz Questions Revisited and Questions from the Audience 17:00 MA06.09: Efficacy RENO Study Results of Oral Martin Schuler, University Hospital Essen, Germany Vinorelbine or Etoposide with Cisplatin & Chemo– and Faculty Panel Radiation in Stage III NSCLC. SLCG 10/02 Dolores Isla, University Hospital Clínico Lozano Blesa, 19:10 ISS08.07: prIME Points™ Spain Martin Schuler, University Hospital Essen, Germany17:06 MA06.10: A Pooled Analysis Comparing the Outcomes 19:15 Adjourn of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC Thomas Stinchcombe, Duke University, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 111
TUESDAY DECEMBER 6 07:00 – 19:30 WARDROBE OPEN 08:10 SH04.03: Pulmonology Hall C Egbert Smit, Netherlands Cancer Institute, The Netherlands Exit U2 Station ‘Krieau’ 07:00 – 16:30 REGISTRATION OPEN 07:30 – 08:30 MTE10: Unique Biologic Aspects of Tobacco– Foyer D Induced Lung Cancer (Ticketed Session) Exit U2 Station ‘Krieau’ TRACK: BIOLOGY/PATHOLOGY ROOM: SCHUBERT 1, LEVEL ONE 07:00 – 16:30 SPEAKER READY ROOM OPEN 07:30 MTE10.01: Unique Biologic Aspects of Tobacco–Induced Hall C Lung Cancer Mauro Papotti, University of Turin, Italy 09:30 – 16:30 EXHIBIT HALL OPEN Hall B (Exhibit Hall) Refreshments provided all day 07:30 – 08:30 MTE11:The Clinical Impact of the 2015 WHO Classification of Lung Tumors 07:30 – 08:30 SH03: WCLC 2016 Scientific Highlights – (Ticketed Session) Surgery and Early Stage NSCLC I – III TRACK: BIOLOGY/PATHOLOGY ROOM: SCHUBERT 2, LEVEL ONE TRACK: SURGERY, EARLY STAGE NSCLC, LOCALLY ADVANCED 07:30 MTE11.01: The Clinical Impact of the 2015 WHO NSCLC Classification of Lung Tumors ROOM: Andrew Nicholson, Royal Brompton and Harefield NHS CHAIR: HALL C1 Foundation Trust, UK & Masayuki Noguchi, University of Tsukuba, Japan WALTER KLEPETKO, MEDICAL UNIVERSITY VIENNA, AUSTRIATUESDAY DECEMBER 6 07:30 SH03.01: Surgery Saulus Cicenas, National Cancer Institute, Lithuania 07:50 SH03.02: NSCLC Stage I–II 07:30 – 08:30 MTE12: Clinically Relevant Signal Bernward Passlick, University Hospital Freiburg, Transduction Pathways (Ticketed Session) Germany TRACK: BIOLOGY/PATHOLOGY 08:10 SH03.03: NSCLC Stage III ROOM: SCHUBERT 4 Virginie Westeel, Jean–Minjoz Hospital, France 07:30 MTE12.01: Clinically Relevant Signal Transduction Pathways Balazs Dome, Medical University of Vienna, Austria & Ming Sound, Princess Margaret Cancer Centre, Canada 07:30 – 08:30 SH04: WCLC 2016 Scientific Highlights – 07:30 – 08:30 MTE13: Basic Immunology for the Clinician Screening, Radiology, Staging, Pulmonology (Ticketed Session) TRACK: RADIOLOGY/STAGING/SCREENING, RADIOLOGY/ TRACK: BIOLOGY/PATHOLOGY STAGING, SCREENING, PULMONOLOGY ROOM: SCHUBERT 5 ROOM: HALL C7 CHAIRS: JIRI VOTRUBA, CHARLES UNIVERSITY HOSPITAL & CZECH REPUBLIC & SYLVIA HARTL, INSTITUTION, AUSTRIA 07:30 SH04.01: Screening 07:30 MTE13.01: Basic Immunology for the Clinician James Jett, Nation Jewish Health, USA Marcin Moniuszko, Medical University of Bialystok, Poland & Edgardo Santos, Lynn Cancer Institute, USA 07:50 SH04.02: Radiology/Staging Wilfried Eberhardt, Germany 112 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION07:30 – 08:30 MTE14: How to Implement Screening/ 07:30 – 08:30 MTE18: Perspectives in the Systemic Early Detection in Routine Practice Treatment of Small–Cell Lung Cancer (Ticketed Session) (Ticketed Session) TRACK: RADIOLOGY/STAGING/SCREENING TRACK: SCLC/NEUROENDOCRINE TUMORS ROOM: SCHUBERT 6 ROOM: LEHAR 1–207:30 MTE14.01: How to Implement Screening/Early 07:30 MTE18.01: Perspectives in the Systemic Treatment of Detection in Routine Practice Small–Cell Lung Cancer Harry De Koning, Erasmus MC, The Netherlands & Mary O’Brien, Royal Marsden Hospital, UK & Pieter Sam Janes, UK Postmus, Independent, UK07:30 – 08:30 MTE15: Lymph Node Mapping in Lung Cancer 07:30 – 08:30 MTE19: Monitoring of Treatment Outcome (Ticketed Session) in Clinical Trials and in Routine Practice (Ticketed Session) TRACK: RADIOLOGY/STAGING/SCREENING ROOM: STRAUSS 1 TRACK: CHEMOTHERAPY/TARGETED THERAPY/ IMMUNOTHERAPY07:30 MTE15.01: Lymph Node Mapping in Lung Cancer Kenji Suzuki, Juntendo University Hospital, Japan & ROOM: STOLZ 1 David Waller, Glenfield Hospital, UK 07:30 MTE19.01: Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice Richard Gralla, Albert Einstein College of Medicine, USA & Kostas Syrigos, University of Athens, Greece07:30 – 08:30 MTE16: Precision Medicine in NSCLC: Lessons 07:30 – 08:30 MTE20: Radiotherapy of Locally Advance TUESDAY DECEMBER 6 Learned and Perspectives (Ticketed Session) NCSLC: Selecting the Right Patient for the Right Radiotherapy (Ticketed Session) TRACK: CHEMOTHERAPY/TARGETED THERAPY/ IMMUNOTHERAPY TRACK: RADIOTHERAPY ROOM: STOLZ 2 ROOM: STRAUSS 207:30 MTE16.01: Precision Medicine in NSCLC: Lessons Learned and Perspectives Terufumi Kato, Kanagawa Cancer Center, Japan & 07:30 MTE20.01: Radiotherapy of Locally Advance NCSLC: Christian Manegold, Medical Faculty Mannheim, Selecting the Right Patient for the Right Radiotherapy University of Heidelberg, Germany Dirk De Ruysscher, Maastricht University Medical Center, The Netherlands07:30 – 08:30 MTE17: Maintenance Therapy Versus Early Second–Line Therapy in Advanced NSCLC (Ticketed Session) TRACK: ADVANCED NSCLC ROOM: STRAUSS 307:30 MTE17.01: Maintenance Therapy Versus Early Second– Line Therapy in Advanced NSCLC Tudor Ciuleanu, InstitutulOncologic “Prof. Dr. Ion Chiricuta” Cluj Napoca, Romania & Panos Fidias, Massachussets General Hospital, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 113
07:30 – 08:30 ISS09: Targeted Therapy on the Horizon for 09:45 PL03.07: First–line Ceritinib Versus Chemotherapy SCLC – AbbVie in Patients With ALK–rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND–4) TRACK: INDUSTRY SUPPORTED SYMPOSIUM Gilberto De Castro Jr, Instituto do Câncer do Estado de ROOM: LEHAR 3–4 São Paulo, Brazil CHAIRS: MARTIN RECK, LUNGCLINIC GROSSHANSDORF, 09:55 PL03.08: Discussant GERMANY Fiona Blackhall, Christie Hospital NHS Foundation Trust, UK 07:30 ISS09.01: Challenges in SCLC Across Decades Martin Reck, LungClinic Grosshansdorf, Germany 10:05 PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel 07:40 ISS09.02: Advancing the Study in SCLC – What is the in Advanced Non–Small Cell Lung Cancer (GALAXY–2) Underlying Biology? Rathi Pillai, Winship Cancer Institute, Emory Jean–Charles Soria, Gustave Roussy Cancer Campus, University, USA France 07:55 ISS09.03: Emerging Novel Agents – A New Day for SCLC 10:15 PL03.10: Discussant Treatment David R. Gandara, UC Davis Comprehensive Cancer Ramaswamy Govindan, Washington University School Center, USA of Medicine, USA 08:15 ISS09.04: Panel Discussion: Looking Over the Horizon – Future Treatment of SCLC All Faculty 10:25 – 11:00 NETWORKING OPPORTUNITY & POSTER PRESENTERS PRESENT FOR 08:25 ISS09.05: Question & Answer P2 POSTERS All Faculty Hall B (Exhibit Hall) Refreshments provided 08:35 – 10:25 PL03: Presidential Symposium 10:30 – 11:45 PR03: Press Conference ROOM: HALL D (PLENARY HALL) ROOM: SCHUBERT 1, LEVEL ONE CHAIRS: DAVID CARBONE, THE OHIO STATE WEXNER For information on topics and speakers, please visit MEDICAL CENTER, USA & ROBERT PIRKER, MEDICAL the Press & Media page on the Conference website at UNIVERSITY OF VIENNA, AUSTRIA wclc2016.iaslc.org/press-media/press-media/ 08:35 PL03.01: Presidential Address David Carbone, The Ohio State Wexner Medical Center, USATUESDAY DECEMBER 6 08:45 PL03.02: Lung Cancer Staging – Changing the Clinical 11:00 – 12:30 ED07: Classification and Druggable Targets Practice of Thoracic Tumors Ramon Rami–Porta, Hospital Universitari Mutua Terrassa, and CIBERES Lung Cancer Group, Spain TRACK: BIOLOGY/PATHOLOGY 09:05 PL03.03: Randomised Phase III Study of Osimertinib ROOM: HALL C1 vs Platinum–Pemetrexed for EGFR T790M–Positive Advanced NSCLC (AURA3) CHAIRS: ADI GAZDAR, UNIVERSITY OF TEXAS Vassiliki Papadimitrakopoulou, Thoracic/Head and SOUTHWESTERN MEDICAL CENTER & HELMUT Neck Medical Oncology, The University of Texas, MD POPPER, MEDICAL UNIVERSITY GRAZ, AUSTRIA Anderson Cancer Center, USA 11:00 ED07.01: Adenocarcinomas and Squamous Cell Carcinomas William Travis, Memorial Sloan Kettering Cancer Center, USA 09:15 PL03.04: Discussant 11:20 ED07.02: The 2015 WHO Classification of Tetsuya Mitsudomi, Kindai University Faculty of Neuroendocrine Tumors Medicine, Japan Elisabeth Brambilla, CHU Grenoble, France 09:25 PL03.05: BRAIN: A Phase – Trial Comparing WBI and 11:40 ED07.03: The 2015 WHO Classification of Tumors of Chemotherapy with Icotinib in NSCLC with Brain the Pleura Metastases Harboring EGFR Mutations (CTONG 1201) R ichard Attanoos, UK Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy 12:00 ED07.04: The WHO Classification of Thymomas and of Medical Sciences, China Thymic Carcinomas Alexander Marx, University Medical Centre Mannheim, 09:35 PL03.06: Discussant Germany Jacek Jassem, Medical University of Gdansk, Poland 12:20 Q&A 114 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION11:00 – 12:30 SC13: Interaction of COPD and Lung Cancer 11:00 – 12:30 SC15: Clinical Trials: How to set Priorities? – Consequences for Early Diagnosis and Management TRACK: TRIAL DESIGN/STATISTICS ROOM: HALL C8 TRACK: RADIOLOGY/STAGING/SCREENING CHAIRS: ROLF STAHEL, UNIVERSITY HOSPITAL ZURICH, ROOM: STOLZ 1 SWITZERLAND & YI LONG WU, GUANGDONG LUNG CANCER INSTITUTE, CHINA CHAIRS: ANEE–PASCALE MEERT, INSTITUT JULES BORDET, BELGIUM & KONSTANTINOS ZAROGOULIDIS, G. 11:00 SC15.01: The American Perspective PAPANIKOLAOU HOSPITAL, GREECE Suresh Ramalingam, Winship Cancer Institute of Emory University, USA11:00 SC13.01: Common Pathogenesis of COPD and Lung Cancer K wun Fong, The Prince Charles Hospital UQ Thoracic Res 11:15 SC15.02: The European Perspective Centre, Australia Rolf Stahel, University Hospital Zurich, Switzerland11:20 SC13.02: Increased Risk for Lung Cancer in COPD 11:30 SC15.03: The Chinese Perspective Stephen Lam, British Columbia Cancer Agency, Canada Yi Long Wu, Guangdong Lung Cancer Institute, China11:40 SC13.03: Limitation by COPD for Diagnostic Procedures 11:45 SC15.04: The Japanese Perspective Gyula Ostoros, Orszagos Koranyi TBC es Pulmonologiai Yuichiro Ohe, National Cancer Center Hospital, Japan Intezet, Hungary 12:00 SC15.05: The South American Perspective 12:00 SC13.04: Limitations by COPD for Treatment Gilberto Castro, University of Sao Paulo, Brazil Yoichi Nakanishi, Kyushu University, Japan 12:15 Q&A12:20 Q&A11:00 – 12:30 SC14: Immunotherapy of NSCLC 11:00 – 12:30 IA05: The Practical Use of the TNM TUESDAY DECEMBER 6 Classifications for Thoracic Cancers TRACK: CHEMOTHERAPY/TARGETED THERAPY/ IMMUNOTHERAPY TRACK: RADIOLOGY/STAGING/SCREENING ROOM: HALL C7 ROOM: HALL C2 CHAIRS: HISAO ASAMURA, KEIO UNIVERSITY SCHOOL OF CHAIRS: NAIYER RIZVI, COLUMBIA UNIVERSITY MEDICAL MEDICINE, JAPAN & CHRISTIAN HEROLD, MEDICAL CENTER, USA & CHRISTOPH ZIELINSKI, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA UNIVERSITY VIENNA, AUSTRIA 11:00 IA05.01: Lung Cancer Cases 11:00 SC14.01: Immunotherapy in the First–Line Setting of Gustavo Lyons, Buenos Aires British Hospital, Argentinia Advanced NSCLC Roy Herbst, Yale School of Medicine, Yale Cancer Center, 11:30 IA05.02: Mesothelioma Cases and Smilow Cancer Hospital, USA Mir Hoda, Medical University Vienna, Austria11:20 SC14.02: Immunotherapy in the Second–Line Setting of 11:50 IA05.03: Thymic Carcinoma Cases Advanced NSCLC Frank Detterbeck, Yale University, USA Luis Paz–Ares, Hospital universitario Doce de Octubre, Spain 12:10 IA05.04: Esophageal Carcinoma Cases Thomas Rice, USA11:40 SC14.03: Combination Immunotherapy – Basic Considerations and First Outcomes David Spigel, Sarah Cannon, USA11:55 SC14.04: The CD47 Macrophage Checkpoint as a New Immunotherapy Target Branimir Sikic, Stanford University, USA12:10 SC14.05: Tobacco Use and Immunotherapy Anne–Marie Dingemans, Maastricht University Medical Center, Netherlands WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 115
11:00 – 12:30 IA06: Interactive Session Staging Group II 11:00 – 12:30 OA09: Locally Advanced NSCLC: (Ticketed Session) Innovative Treatment Strategies TRACK: RADIOLOGY/STAGING/SCREENING TRACK: LOCALLY ADVANCED NSCLC ROOM: SCHUBERT 3 ROOM: STRAUSS 3 COORDINATORS: KARIN DIECKMANN, MEDICAL UNIVERSITY CHAIRS: WALTER CURRAN, WINSHIP CANCER INSTITUTE, USA OF VIENNA, AUSTRIA & HELMUT PROSCH, & MYUNG–JU AHN, SAMSUNG MEDICAL CENTER, MEDICAL UNIVERSITY OF VIENNA, SOUTH KOREA AUSTRIA 11:00 IA06.01: Interactive Session 11:00 OA09.01: The Number or the Position is the Main StagingL ibor Havel, Czech Republic, Anna Kerpel- Prognostic Factor for N2 NSCLC? A Validation of New Fronius, Hungary & Elisabeth Stiefsohn, Austria IASLC N Staging Proposal Sara Ricciardi, Divison of Thoracic Surgery, University Hospital of Pisa, Italy 11:10 OA09.02: Should Surgery Be Part of the Multimodality Treatment for Stage IIIB Non–Small Cell Lung Cancer 11:00 – 12:30 NU03: Supporting Patients Receiving Stephane Collaud, Marie Lannelongue Hospital, France Treatment 11:20 OA09.03: Randomized Controlled Study Comparing TRACK: NURSES Adjuvant versus Neo–Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC ROOM: SCHUBERT 5 Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational CHAIRS: VANESSA BEATTIE, AINTREE UNIVERSITY HOSPITAL, Medicine in Lung Cancer, Guangdong General Hospital & UK & MARY DUFFY, PETER MACCALLUM CANCER Guangdong Academy of Medical Sciences, China CENTRE, AUSTRALIA 11:00 NU03.01: Supporting Patients Undergoing Radical Treatments EPD – MARS Study Angela Tod, The University of Sheffield, UK 11:30 OA09.04: Discussant Masahiro Tsuboi, National Cancer Center Hospital East, 11:20 NU03.02: eHealth and Remote Patient Monitoring and Japan Supportive Care in Thoracic Oncology Roma Maguire, University of Surrey, UK 11:45 OA09.05: Positron Emission Tomography (PET) with 18F–Fluoroazomycin Arabinoside (FAZA) to Assess 11:40 NU03.03: Supportive Care in Patients Receiving Tumor Hypoxia in Non–Small Cell Lung Cancer (NSCLC) Systemic Therapy Alexander Sun, University of Toronto, Canada Tanja Cufer, University Clinic Golnik, Slovenia 11:55 OA09.06: Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non–Small 12:00 Q&A Cell Lung Cancer (NSCLC) Krista Wink, Maastro Clinic, Netherlands 12:05 OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced? Technologies Benefit Stage –TUESDAY DECEMBER 6 11:00 – 12:30 PA03: Patient Support and Involvement in NSCLC Treated with CCRT Research Baosheng Li, Shandong Cancer Hospital, China TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS 12:15 OA09.08: Discussant ROOM: SCHUBERT 6 Paul Van Houtte, Institut Jules Bordet, Belgium CHAIRS: JENNIFER KING, LUNG CANCER ALLIANCE, USA & PAWEL MUSZUMANSKI, INSTITUTION, POLAND 11:00 PA03.01: Central European Lung Cancer Patient Network (CELCAPANET) Franz Buchberger, Lungenkrebsforum Austria, Austria 11:00 – 12:30 OA10: EGFR Mutations 11:15 PA03.02: Psycho–Social and Communication Needs of TRACK: BIOLOGY/PATHOLOGY Cancer Patients: Romanian Results ROOM: STRAUSS 1 Csaba Dégi, Romania, Romania CHAIRS: JAMES SPICER, GUY’S & ST. THOMAS’ NHS TRUST; 11:30 PA03.03: How to Live with Lung Cancer? The Slovenian KING’S COLLEGE LONDON, UK & TERUFUMI KATO, Lung Cancer Patient Support KANAGAWA CANCER CENTER, JAPAN Andreja Cirila Škufca Smrdel, 1. Institute of Oncology Ljubljana, 2. Cancer Patients’ Association of Slovenia, 11:00 OA10.01: Comprehensive Genomic Profiling and PDX Slovenia Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade 11:45 PA03.04: Patient Involvement in the Evaluation of Jonathan Riess, UC Davis Comprehensive Cancer Center, Cancer Medicines: The EMA Experience USA Nathalie Bere, European Medicines Agency, UK 12:00 Q&A 116 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION11:10 OA10.02: Association of Variations in HLA–Class II and 11:30 OA11.04: Discussant Other Loci with Susceptibility to EGFR–Mutated Lung Maurice Pérol, Centre Léon Bérard, France Adenocarcinoma Takashi Kohno, National Cancer Center Research 11:45 OA11.05: A Phase 2 Study of Cabozantinib for Patients Institute, Japan with Advanced RET–Rearranged Lung Cancers Alexander Drilon, Memorial Sloan Kettering Cancer11:20 OA10.03: YAP–NOTCH and STAT3 Signaling Rebound as Center, USA a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer 11:55 OA11.06: Role of Fibroblasts in the Subtype–Specific Rafael Rosell, Catalan Institute of Oncology, Spain Therapeutic Effects of Nintedanib in Non–Small Cell Lung Cancer (NSCLC)11:30 OA10.04: Discussant J ordi Alcaraz, Facultat de Medicina, Universitat de Hossein Borghaei, Fox Chase Cancer Center, USA Barcelona, Spain11:45 OA10.05: EGFR Gene Mutations Affect Tumor– 12:05 OA11.07: Combining Anti–Angiogenesis and Infiltrating Stromal Cell Components in Early–Stage Immunotherapy Enhances Antitumor Effect by Lung Adenocarcinoma Promoting Immune Response in Lung Cancer Toshiyuki Shima, Keio University School of Medicine, Sha Zhao, Shanghai Pulmonary Hospital, Thoracic Japan Cancer Institute, Tongji University School of Medicine, China11:55 OA10.06: Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study) 12:15 OA11.08: Discussant Julien Mazieres, Centre Hospitalier Universitaire, France Rainer Wiewrodt, Muenster University Hospital, Germany12:05 OA10.07: Report on Liquid Biopsies from Advanced Lung Adenocarcinoma Patients and Correlation with Their Tumor Biopsy Profiles 11:00 – 12:30 OA12: SBRT and Other Issues in Early Stage Edgardo Santos, Lynn Cancer Institute/Florida Atlantic NSCLC University, USA TRACK: EARLY STAGE NSCLC12:15 OA10.08: Discussant Frederico Cappuzzo, AUSL della Romagna, Italy ROOM: STRAUSS 2 CHAIRS: DIRK DE RUYSSCHER, MAASTRICHT UNIVERSITY TUESDAY DECEMBER 6 MEDICAL CENTER, NETHERLANDS & MICHAEL MUELLER, OTTO WAGNER HOSPITAL, AUSTRIA11:00 – 12:30 OA11: Angiogenesis in Advanced Lung Cancer 11:00 OA12.01: Phase II Randomized Study of 2 SBRT Regimens for Medically Inoperable Patients with Node TRACK: ADVANCED NSCLC Negative Peripheral NSCLC ROOM: STOLZ 2 Jorge A. Gomez Suescun, Roswell Park Cancer Institute, CHAIRS: LUIS MONTUENGA, CIMA. UNIVERSITY OF NAVARRA, USA SPAIN & JOHN HEYMACH, THE UNIVERSITY OF TEXAS 11:10 OA12.02: Excellent Survival Achieved by Stereotactic MD ANDERSON CANCER CENTER, USA Body Radiotherapy for Medically Operable and Young (< 75 Years) Patients with Stage I Lung Cancer 11:00 OA11.01: Prolonged OS of Patients Exposed to Weekly Hiroshi Onishi, University of Yamanashi, Japan Paclitaxel and Bevacizumab: Impact of the Cross–Over in the IFCT–1103 ULTIMATE Study 11:20 OA12.03: Percutaneous Cryoablation for Lung Cancer Alexis Cortot, Lille University Hospital, France Patients for Whom Surgery or Radiotherapy is Contraindicated Due to Idiopathic Pulmonary Fibrosis 11:10 OA11.02: Randomized Phase 1b/3 Study of Erlotinib plus Takashi Ohtsuka, Keio University, School of Medicine, Ramucirumab in First–Line EGFR Mut + Stage IV NSCLC: Japan Phase 1b Safety Results K azuhiko Nakagawa, Kindai University Faculty of 11:30 OA12.04: Discussant Medicine, Japan Matthias Guckenberger, University Hospital Zurich (UniversitätsSpital Zürich), Switzerland11:20 OA11.03: A Randomized, Multi–Center, Double–Blind Phase II Study of Fruquintinib in Patients with Advanced Non–Small Cell Lung Cancer 11:45 OA12.05: Noninvasive CT–Based Image Biopsy System Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong (iBiopsy) for Early Stage Lung Adenocarcinoma University, China Dawei Yang, Zhongshan Hospital Fudan University, China WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 117
11:55 OA12.06: A Retrospective Analysis of Patients with 12:00 MA07.09: Mass Spectrometry Profiling and Imaging Small Lung Adenocarcinoma (≤2cm) by New World Platform for Novel Precision Drug Resistance Health Organization Classification Biomarkers Discovery in EML4–ALK Lung Keita Nakao, Graduate School of Medicine, The Adenocarcinoma University of Tokyo, Japan Patrick Ma, WVU Cancer Institute, USA 12:05 OA12.07: Selection for Adjuvant Chemotherapy in Stage 12:06 MA07.10: HDAC Inhibition Overcomes Crizotinib– IB Non–Small Cell Lung Cancer: A Propensity Score– Resistance by Mesenchymal–Epithelial Transition Matched Analysis (MET) in EML4–ALK Lung Cancer Cells Jae Hyun Jeon, National Cancer Center, South Korea Koji Fukuda, Kanazawa University, Japan 12:15 OA12.08: Discussant 12:12 MA07.11: Safety and Efficacy of Lorlatinib (PF– Ryuichi Waseda, Fukuoka University, Japan 06463922) in Patients with Advanced ALK+ or ROS1+ Non–Small–Cell Lung Cancer (NSCLC) E Felip, Vall d’Hebron Institute of Oncology, Spain 11:00 – 12:30 MA07: ALK–ROS1 in Advanced NSCLC 12:18 MA07.12: Discussant Robert Doebele, University of Colorado, USA TRACK: ADVANCED NSCLC 11:00 – 12:30 MA08: Treatment Monitoring in Advanced ROOM: LEHAR 1–2 NSCLC CHAIRS: NAVNEET SINGH, POSTGRADUATE INSTITUTE OF TRACK: ADVANCED NSCLC MEDICAL EDUCATION AND RESEARCH (PGIMER), INDIA & JÜRGEN WOLF, UNIVERSITÄTSKLINIKUM ROOM: LEHAR 3–4 KÖLN, GERMANY CHAIRS: ROMAN PEREZ–SOLER, MONTEFIORE MEDICAL 11:00 MA07.01: Updated Pooled Analysis of CNS Endpoints in CENTER, USA & THANYANAN REUNGWETWATTANA, Two Phase II Studies of Alectinib in ALK+ NSCLC RAMATHIBODI HOSPITAL, THAILAND Sai–Hong Ignatius Ou, University of California, Irvine School of Medicine, USA 11:06 MA07.02: Updated Efficacy and Safety Data from the 11:00 MA08.01: A Highly Sensitive Next–Generation Phase 2 NP28761 Study of Alectinib in ALK–Positive Sequencing Platform for Detection of NSCLC EGFR Non–Small–Cell Lung Cancer T790M Mutation in Urine and Plasma Shirish Gadgeel, Karmanos Cancer Institute/Wayne Heather Wakelee, Stanford Cancer Institute, USA State University, USA 11:12 MA07.03: Alectinib (ALC) versus Crizotinib (CRZ) 11:06 MA08.02: Clinical Research Platform into Molecular in ALK–Positive Non–Small Cell Lung Cancer (ALK+ Testing, Treatment, Outcome (CRISP): A Prospective NSCLC): Primary Results from Phase III Study (J–ALEX) German Registry in Stage IV NSCLC AIO–TRK–0315 Young Kim, Kyoto University, Japan Frank Griesinger, Pius Hospital Oldenburg, Germany 11:18 MA07.04: Discussant 11:12 MA08.03: Osimertinib vs Platinum–Pemetrexed for Benjamin Besse, Gustave Roussy, France T790M–Mutation Positive Advanced NSCLC (AURA3):TUESDAY DECEMBER 6 Plasma ctDNA Analysis 11:30 MA07.05: EUCROSS: A European Phase II Trial of Yi Long Wu, Guangdong Lung Cancer Institute, Crizotinib in Advanced Adenocarcinoma of the Lung Guangdong General Hospital and Guangdong Academy Harboring ROS1 Rearrangements – Preliminary Results of Medical Sciences, China S ebastian Michels, University Hospital of Cologne, Germany 11:18 MA08.04: Discussant Baohui Han, Shanghai Chest Hospital, Shanghai Jiao 11:36 MA07.06: Crizotinib in ROS1 Rearranged or MET Tong University, China Deregulated Non–Small–Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial 11:30 MA08.05: Depth of Response to First–Line EGFR TKI Lorenza Landi, Istituto Toscano Tumori, Italy Does Not Predict Survival in EGFR–Mutated NSCLC Patients 11:42 MA07.07: Ceritinib in ROS1–Rearranged Non–Small–Cell Ting–Hui Wu, National Taiwan University Hospital, Lung Cancer: An Update of Korean Nationwide Phase II Taiwan Study Byoung Chul Cho, Yonsei Cancer Center, Yonsei 11:36 MA08.06: Impact of Depth of Response (DpR) on University College of Medicine, South Korea Survival in Patients with Advanced NSCLC Treated with First–Line Chemotherapy 11:48 MA07.08: Discussant Daniel Morgensztern, Washington University School of Enriqueta Felip, Hospital Universitari Vall d’Hebron, Medicine in St. Louis, USA Spain 11:42 MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE) Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China 118 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION11:48 MA08.08: Discussant 14:20 – 15:50 OA13: Immunotherapy in Malignant Pleural Aaron Mansfield, Mayo Clinic, USA Mesothelioma: Current Status of Trials and New Approaches12:00 MA08.09: Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients Katja Mohorcic, University Clinic of Respiratory and TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ Allergic Diseases Golnik, Slovenia ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES12:06 MA08.10: Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired ROOM: STOLZ 1 Resistance to EGFR–TKI (WJOG8014LTR) Koichi Azuma, Kurume University School of Medicine, CHAIRS: RAFFIT HASSAN, NATIONAL CANCER INSTITUTE, USA Japan & PAUL BAAS, THE NETHERLANDS CANCER INSTITUE, NETHERLANDS 14:25 OA13.01: A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational12:12 MA08.11: Monitoring the Emergence of EGFR T790M Research (TR) Biopies ctDNA in Urine from EGFR Mutated NSCLC Patients to Paul Baas, The Netherlands Cancer Institue, Netherlands Predict Response to 3rd Generation Anti–EGFR TKIs Hatim Husain, UCSD Moores Cancer Center, USA 14:30 OA13.02: Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis 12:18 MA08.12: Discussant Hedy Kindler, University of Chicago, USA Martin Filipits, Medical University of Vienna, Austria 14:40 OA13.03: Long–Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE–028 Evan Alley, University of Pennsylvania, USA12:45 – 14:15 ISS10: Novel Treatment Strategies for 14:50 OA13.04: Discussant ALK+ NSCLC: From Evidence to Practice Cornelius Waller, Universitätsklinikum Freiburg, – Novartis Germany TRACK: INDUSTRY SUPPORTED SYMPOSIUM 15:05 OA13.05: Somatic Genetic Alterations and Immune Microenvironment in Malignant Pleural Mesothelioma ROOM: LEHAR 3–4 Wickii Vigneswaran, Loyola University Health System, TUESDAY DECEMBER 6 USA CHAIR: SOLANGE PETERS, LAUSANNE UNIVERSITY HOSPITAL CHUV, SWITZERLAND12:45 ISS10.01: Welcome & Introduction 15:15 OA13.06: Autologous Dendritic Cells Loaded with Solange Peters, Lausanne University Hospital CHUV, Allogeneic Tumor Cell Lysate (Pheralys®) in Patients Switzerland with Mesothelioma: Final Results of a Phase I Study Joachim Aerts, Erasmus MC Cancer Centre, Netherlands12:50 ISS10.02: ALK+ NSCLC: Not Your Typical Patients 15:26 OA13.07: Intrapleural Modified Vaccine Strain Measles Heather Wakelee, Stanford University School of Virus Therapy for Patients with Malignant Pleural Medicine, USA Mesothelioma Tobias Peikert, Mayo Clinic, USA13:05 ISS10.03: Optimizing Outcomes for Your ALK+ NSCLC Patients Fabrice Barlesi, Aix–Marseille University, France 15:35 OA13.08: Discussant Anna Nowak, University of Western Australia, Australia13:20 ISS10.04: The Future of ALK+ NSCLC Treatment and What this Implies for Your Clinical Practice D aniel Shao–Weng Tan, National Cancer Centre Singapore, Singapore13:40 ISS10.05: Panel Discussion: Challenges in Sequencing Therapy for Your ALK+ NSCLC Patients All Faculty14:10 ISS10.06: Conclusion and Close Solange Peters, Lausanne University Hospital CHUV, Switzerland WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 119
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION07:30 – 08:30 MTE23: Biomarker Characterization: 07:30 – 08:30 MTE27: Treatment of Lung Cancer Patients Challenges and Perspectives with Poor Performance Status (Ticketed Session) (Ticketed Session) TRACK: BIOLOGY/PATHOLOGY TRACK: PALLIATIVE CARE/ETHICS ROOM: SCHUBERT 3 ROOM: LEHAR 1–207:30 MTE23.01: Biomarker Characterization: Challenges and 07:30 MTE27.01: Treatment of Lung Cancer Patients with Poor Perspectives Performance Status Leonhard Müllauer, Medical University Vienna, Austria Rogerio Lilenbaum, Yale Cancer Center, USA & Luboš & Rafael Rosell, Catalan Institute of Oncology, Germans Petruzelka, Charles University, Czech Republic Trias i Pujol Health Sciences Institute and Hospital, Spain 07:30 – 08:30 MTE28: Implementation of Precision Medicine in Routine Practice: The Latin07:30 – 08:30 MTE24: Immunohistochemical Assessment American Experience of Biomarkers for Immune Checkpoint (Ticketed Session) Inhibitors (Ticketed Session) TRACK: REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH TRACK: BIOLOGY/PATHOLOGY ROOM: SCHUBERT 4 ROOM: LEHAR 3–407:30 MTE24.01: Immunohistochemical Assessment of 07:30 MTE28.01: Implementation of Precision Medicine in Biomarkers for Immune Checkpoint Inhibitors Routine Practice: The Latin American Experience Vera Capelozzi, Faculty of Medicine, University of São Mercedes Dalurzo, Hospital Italiano de Buenos Aires, Paulo, Brazil Argentinia & Marileila Varella–Garcia, University of Colorado School of Medicine, USA07:30 – 08:30 MTE25: Radiotherapy in Small Cell 07:30 – 08:30 MTE29: Advances in Malignant Pleural Lung Cancer Mesothelioma (Ticketed Session) (Ticketed Session) TRACK: SCLC/NEUROENDOCRINE TUMORS TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ ROOM: SCHUBERT 5 ROOM: ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES07:30 MTE25.01: Radiotherapy in Small Cell Lung Cancer Cecile Le Pechoux, Gustave Roussy, France & Andrew STOLZ 1 Turrisi, Institution, Germany 07:30 MTE29.01: Advances in Malignant Pleural Mesothelioma Paolo Boffetta, Icahn School of Medicine at Mount Sinai, USA & Nico Van Zandwijk, University of Sydney, WEDNESDAY DECEMBER 7 Asbestos Diseases Research Institute, Australia07:30 – 08:30 MTE26: EGFR Targeted Therapies: Lessons Learned (Ticketed Session) TRACK: CHEMOTHERAPY/TARGETED THERAPY/ IMMUNOTHERAPY ROOM: SCHUBERT 607:30 MTE26.01: EGFR Targeted Therapies: Lessons Learned Frederico Cappuzzo, AUSL della Romagna, Italy & Shun Lu, Shanghai Chest Hospital, Jiao Tong University, China WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 131
07:30 – 08:30 MTE30: Non–intubated Thoracic Surgery 09:45 – 10:15 PL04b: Plenary Keynote Lecture (Ticketed Session) ROOM: HALL D (PLENARY HALL) TRACK: SURGERY CHAIRS: FRED HIRSCH, USA & ROBERT PIRKER, AUSTRIA ROOM: STOLZ 2 09:45 PL04b.01: The Role of Doctors in a Globalized World 07:30 MTE30.01: Non–intubated Thoracic Surgery Alfred Gusenbauer, Former Federal Chancellor of the Teodor Horvath, Czech Republic, Jin-Shing Chen, Taiwan Republic of Austria & Ya-Jung Cheng, Taiwan 07:30 – 08:30 WS09: Special Workshop: 10:25 – 11:00 NETWORKING OPPORTUNITY & Tobacco Free Portfolios POSTER PRESENTERS PRESENT FOR P3 POSTERS TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND Hall B (Exhibit Hall) CESSATION/PREVENTION Refreshments provided ROOM: STRAUSS 2 07:30 WS09.01: Learn How to Change the World for the Better – One Pension Fund at a Time! B ronwyn King, Tobacco Free Portfolios, Australia 10:30 – 11:45 PR03: Press Conference 08:45 – 09:40 PL04a: Immune Checkpoint ROOM: SCHUBERT 1, LEVEL ONE Inhibitors in Advanced NSCLC For information on topics and speakers, please visit the Press & Media page on the Conference website at TRACK: ADVANCED NSCLC wclc2016.iaslc.org/press-media/press-media/ ROOM: HALL D (PLENARY HALL) CHAIRS: JEAN-CHARLES SORIA, FRANCE & CAICUN ZHOU, CHINA 08:45 PL04a.01: Health–Related Quality of Life for 11:00 – 12:30 ED11: Advanced NSCLC: Pembrolizumab vs Chemotherapy in Advanced NSCLC State–of–the–Art Treatment with PD–L1 TPS ≥50%: Data from KEYNOTE–024 Julie Brahmer, Sidney Kimmel Comprehensive Cancer TRACK: ADVANCED NSCLC Center at Johns Hopkins, USA ROOM: HALL C8 08:55 PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced CHAIRS: CHRISTIAN MANEGOLD, MEDICAL FACULTY NSCLC: Results from Subgroup Analyses MANNHEIM, UNIVERSITY OF HEIDELBERG, GERMANY Shirish Gadgeel, Karmanos Cancer Institute/Wayne & CAICUN ZHOU, SHANGHAI PULMONARY HOSPITAL, State University, USA TONGJI UNIVERSITY, CHINA 11:00 ED11.01: Systemic Therapy for Advanced Oncogene– Driven NSCLC 09:05 PL04a.03: Durvalumab in ≥3rd–Line Locally Advanced or D avid R. Gandara, UC Davis Comprehensive Cancer Metastatic, EGFR/ALK Wild–Type NSCLC: Results from Center, USA the Phase 2 ATLANTIC Study Marina Garassino, Fondazione IRCCS Istituto Nazionale 11:25 ED11.02: Systemic Therapy for Advanced Non– dei Tumori, Italy Oncogene–Driven NSCLC Giorgio Scagliotti, University of Torino, Italy 09:15 PL04a.04: Multicentric French Harmonization Study forWEDNESDAY DECEMBER 7 PD–L1 IHC Testing in NSCLC Julien Adam, Gustave Roussy Cancer Campus, France 11:50 ED11.03: Management of Oligo–Metastatic NSCLC Jaroslaw Kuzdzal, Jagiellonian University, Poland 09:25 PL04a.05: Discussant 12:10 ED11.04: Palliative Radiotherapy of Advanced NSCLC Michael Boyer, Chris O’Brien Lifehouse, Australia Karin Dieckmann, Medical University of Vienna, Austria 132 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION 12:00 ED13.05: Systemic Therapy of Inoperable Malignant Pleural Mesothelioma 11:00 – 12:30 ED12: Regional Tobacco Control Policies: Arnaud Scherpereel, Hospital of the University (CHRU) Advances & Challenges of Lille, France TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND 12:15 ED13.06: Mesothelioma in a Setting of Germline BAP1 CESSATION/PREVENTION Mutations Michele Carbone, University of Hawaii Cancer Center, ROOM: HALL C7 USA CHAIRS: ZARIHAH ZAIN, LINCOLN UNIVERSITY COLLEGE MALAYSIA, MALAYSIA & FLORIN MIHALTAN, NATIONAL INSTITUTE OF PNEUMOLOGY, ROMANIA11:00 ED12.01: Tobacco Control Policies in Eastern Europe Gábor Kovács, National Korányi Institute for TB and Pulmonology, Hungary 11:00 – 12:30 SC24: Management of Indeterminate Pulmonary Nodules11:15 ED12.02: Tobacco Control: The Turkish Experience Nazmi Bilir, Hacettepe University, Turkey TRACK: PULMONOLOGY11:30 ED12.03: Tobacco Control: The Indian Experience ROOM: HALL C2 Surendra Shastri, Tata Memorial Center, India CHAIRS: NEVENA SECEN, INSTITUTE FOR PULMONARY11:45 ED12.04: Tobacco Control Policies in China DISEASES OF VOJVODINA, SERBIA & OLEG PIKIN, Xiuyi Zhi, Xuanwu Hospital, Capital Medical University, HERTZEN RESEARCH INSTITUTE OF ONCOLOGY, China RUSSIA 11:00 SC24.01: Risk Assessment in the Management of Pulmonary Nodules 12:00 ED12.05: Tobacco Control Policies in Japan Satoshi Shiono, Yamagata Prefectural Central Hospital, Tomotaka Sobue, Osaka University, Japan Japan12:15 ED12.06: Tobacco Control Policies in Latin America 11:20 SC24.02: Radiological Techniques for the Evaluation of Nise Yamaguchi, Hospital Albert Einstein, Brazil Pulmonary Nodules Reginald Munden, Wake Forest Baptist Medical Center, USA11:00 – 12:30 ED13: Treatment of Malignant Pleural 11:35 SC24.03: The Role of the Pulmonologist in the Mesothelioma Management of Pulmonary Nodules Philippe Lambin, The Netherlands TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC 11:50 SC24.04: The Role of the Pathologist in the MALIGNANCIES Management of Indeterminate Pulmonary Nodules Keith Kerr, Aberdeen University Medical School, UK ROOM: HALL C1 12:10 SC24.05: Indication and Techniques of Surgery CHAIRS: HEDY KINDLER, UNIVERSITY OF CHICAGO, USA & Ugo Pastorino, Fondazione IRCCS Istituto Nazionale NICO VAN ZANDWIJK, UNIVERSITY OF SYDNEY, Tumori, Italy AUSTRALIA11:00 ED13.01: Biomarkers in Malignant Pleural Mesothelioma Harvey Pass, NYU Langone Medical Center, USA WEDNESDAY DECEMBER 711:15 ED13.02: Tissue–Based Biomarkers Glen Reid, Asbestos Diseases Research Institute, Australia11:30 ED13.03: Surgery with Adjuvant or Induction Radiotherapy Marc De Perrot, Institution, Canada11:45 ED13.04: Systemic Induction Therapy of Malignant Pleural Mesothelioma Paul Baas, Netherlands Cancer Institute, Netherlands WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 133
11:00 – 12:30 SC25: The Role of Surgeons in Multimodality 11:00 – 12:30 SC27: P53 and KRAS Mutations in NSCLC Clinical Trials TRACK: BIOLOGY/PATHOLOGY TRACK: SURGERY ROOM: STRAUSS 3 CHAIRS: FILIPPO DE MARINIS, EUROPEAN INSTITUTE OF ROOM: STRAUSS 2 ONCOLOGY, ITALY & HIDEO KUNITOH, JAPANESE RED CHAIR: NORIHIKO IKEDA, TOKYO MEDICAL UNIVERSITY, CROSS MEDICAL CENTER, JAPAN JAPAN & GEORGIOS STAMATIS, RUHRLANDKLINIK/ UNIVERSITY ESSEN, GERMANY 11:00 SC27.01: The Role of p53 in Lung Cancer Pierre Hainaut, International Agency for Research on 11:00 SC25.01: Trial Design for Multimodality Treatment of Cancer, France NSCLC David Jones, Memorial Sloan Kettering Cancer Center, 11:20 SC27.02: Biology of KRAS Mutations USA József Tímár, Semmelweis University (SE), Hungary 11:20 SC25.02: Quality of Resection in Induction and Adjuvant 11:40 SC27.03: Transforming KRAS into a Clinically Relevant Clinical Trials Biomarker Eric Vallieres, Swedish Cancer Institute, USA Kenneth O’Byrne, Princess Alexandra Hospital, Australia 11:40 SC25.03: Quality of Centers and Patient Inclusion 12:00 SC27.04: KRAS–Directed Drug Therapy in Advanced John Edwards, Sheffield Teaching Hospitals NHS NSCLC Foundation Trust, UK P asi Jänne, Dana Farber Cancer Institute, USA 12:00 SC25.04: The Importance of Cooperation: The Essen 12:20 Q&A Experience Wilfried Eberhardt, University of Essen, Germany 12:20 Multimodality Trials: The Chinese Experience 11:00 – 12:30 SC28: Novel Clinical Trial Designs Ke-Neng Chen, China TRACK: TRIAL DESIGN/STATISTICS 11:00 – 12:30 SC26: Angiogenesis Inhibition: ROOM: LEHAR 1–2 Advances & Perspectives CHAIRS: STEFAN MICHIELS, GUSTAVE ROUSSY, FRANCE & TRACK: BIOLOGY/PATHOLOGY LOTHAR PILZ, UNIVERSITY OF HEIDEBERG, MEDICAL FACULTY MANNHEIM, GERMANY ROOM: LEHAR 3–4 11:00 SC28.01: Phase I Trials of Targeted Therapies CHAIRS: TAKASHI SETO, NATIONAL KYUSHU CANCER CENTER, Alex Adjei, Roswell Park Cancer Institute, USA JAPAN & ROSS SOO, NATIONAL UNIVERSITY HEALTH SYSTEM, SINGAPORE 11:20 SC28.02: Umbrella and Basket Designs D aniel Shao–Weng Tan, National Cancer Centre 11:00 SC26.01: Biology of Angiogenesis Singapore, Singapore John Heymach, The University of Texas MD Anderson Cancer Center, USA 11:40 SC28.03: Biomarker “Test and Validation” Designs Mary Redman, Fred Hutchinson Cancer Research Center, 11:20 SC26.02: Angiogenesis Inhibition in Lung Cancer: USA Recent Advances and Perspectives Michael Boyer, Chris O’Brien Lifehouse, Australia 12:00 SC28.04: Adaptive Clinical Trial Designs Vassiliki Papadimitrakopoulou, MD Anderson Cancer 11:40 SC26.03: Predictive Biomarkers for Angiogenesis Center, USA Inhibitors: An Update Martin Reck, Lungen Clinic Grosshansdorf, Germany 12:20 Q&A 12:00 SC26.04: Novel Imaging Technique Stefan Schönberg, University Medical CenterWEDNESDAY DECEMBER 7 Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany 12:20 Q&A 134 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION 11:30 OA18.04: Discussant Andreas Rimner, Memorial Sloan Kettering Cancer11:00 – 12:30 SC29: Access, Value Assessments and Center, USA Affordability of Novel Therapies 11:45 OA18.05: FDG–PET in Thymic Epithelial Tumors: TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS An Evaluation of Only Resected Tumors Kazuo Nakagawa, National Cancer Center Hospital, ROOM: STRAUSS 1 Japan CHAIRS: MACIEJ KRZAKOWSKI, THE MARIA SKLODOWSKA– 11:55 OA18.06: Treatment, Outcome and Prognostic Factors CURIE MEMORIAL CANCER CENTRE AND INSTITUTE of Patients with Thymic Epithelial Tumors at First OF ONCOLOGY, POLAND & EDUARDO RICHARDET, Recurrence IONC (INSTITUTO ONCOLOGICO DE CORDOBA), Rohit Lal, Guy’s Cancer Centre, UK ARGENTINIA11:00 SC29.01: Affordability of Novel Therapies: A Global Challenge Richard Sullivan, Institute of Cancer Policy, UK 12:05 OA18.07: Quality of Resection and Outcome in Stage III TETs: The French RYTHMIC Network Experience 11:20 SC29.02: Value–Based Assessments in Lung Cancer Nicolas Girard, Hospices Civils de Lyon, France Therapy: The North American Perspective Ronan Kelly, USA 12:15 OA18.08: Discussant Enrico Ruffini, University of Turin, Italy11:40 SC29.03: Value–based Assessments in Lung Cancer Therapy: The ESMO Perspective Nathan Cherny, Shaare Zedek Medical Center, Israel12:00 SC29.04: Solutions for Low–Income Countries 11:00 – 12:30 OA19: Translational Research in Early Stage Gilberto Lopes, Sylvester Comprehensive Cancer Center NSCLC at the University of Miami, USA TRACK: EARLY STAGE NSCLC12:15 SC29.05: The Thai Experience to Overcome High Cost Drug in Cancer ROOM: SCHUBERT 3 Sumitra Thongprasert, Bangkok Chiangmai Hospital, Thailand CHAIRS: GERWIN HELLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & GLENWOOD GOSS, UNIVERSITY OF OTTAWA, CANADA 11:00 OA19.01: A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung11:00 – 12:30 OA18: New Insights in the Treatment of Carcinoma by the SPECS Lung Consortium Thymic Malignancies Raphael Bueno, Brigham and Women’s Hospital/ Harvard Medical School, USA TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC 11:10 OA19.02: Sex Differences Are Detected in the Profile of MALIGNANCIES Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma ROOM: SCHUBERT 2, LEVEL ONE Carmen Behrens, Thoracic/Head and Neck Medical Oncology, USA CHAIR: NICOLAS GIRARD, HOSPICES CIVILS DE LYON, FRANCE & STEFAN WATZKA, AUSTRIA11:00 OA18.01: Postoperative Radiotherapy in Thymic 11:20 OA19.03: Identify Lung Adenocarcinoma in Situ Among WEDNESDAY DECEMBER 7 Epithelial Tumors: Insights from the RYTHMIC Pulmonary Micro–Nodules Through Blood Gene Prospective Cohort Expression Profiles Clémence Basse, Cancer Center, France Baohui Han, Shanghai Chest Hospital, China11:10 OA18.02: Evaluation of a Modified Dosing Regimen (2– 11:30 OA19.04: Discussant Weeks on/1–Week off) of Sunitinib as Part of a Phase II Charles Rudin, Memorial Sloan Kettering Cancer Center, Trial in Thymic Carcinoma USA Arun Rajan, Center for Cancer Research, NCI, NIH, USA 11:45 OA19.05: High Oncofetal Chondroitin Sulfate Expression is an Independent Prognostic Factor of Poor11:20 OA18.03: Safety and Clinical Activity of Avelumab Survival in Early–Stage NSCLC (MSB0010718C; Anti–PD–L1) in Patients with Advanced Z oltan Lohinai, National Koranyi Institute of Thymic Epithelial Tumors (TETs) Pulmonology, Hungary Arun Rajan, Center for Cancer Research, NCI, NIH, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 135
11:55 OA19.06: Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non–Small Cell Lung Cancer 11:00 – 12:30 OA21: Palliative and Supportive Care Gavitt Woodard, University of California, San Francisco, for Lung Cancer Patients USA TRACK: PALLIATIVE CARE/ETHICS 12:05 OA19.07: Difference of Postoperative Survival Due to the Type of EGFR Gene Mutation in Surgically Resected ROOM: SCHUBERT 5 Lung Adenocarcinomas Kazuki Hayasaka, Yamagata Prefectural Central CHAIRS: CARLOS SILVA, HOSPITAL BRITANICO DE BUENOS Hospital, Japan AIRES, ARGENTINIA & HERBERT WATZKE, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA 11:00 OA21.01: Pooled Analysis of the Incidence and Risk of Treatment–Related Pneumonitis with Anti–PD–1/PD–L1 12:15 OA19.08: Discussant Therapies in Cancer Patients Ken Olaussen, Gustave Roussy, France Shaodong Hong, Sun Yat–sen University Cancer Center, China 11:10 OA21.02: ALK–Rearranged Non–Small Cell Lung Cancer is Associated with a High Rate of Venous 11:00 – 12:30 OA20: Immunotherapy and Markers Thromboembolism Alona Zer, Rabin Medical Center, Israel TRACK: BIOLOGY/PATHOLOGY ROOM: STOLZ 2 11:20 OA21.03: Unmet Needs in Physical and Emotional Side CHAIR: MARTIN FRÜH, KANTONSSPITAL ST. GALLEN, Effects during Lung Cancer Treatment and Survivorship Jennifer King, Lung Cancer Alliance, USA SWITZERLAND & CLARISSA BALDOTTO, BRAZIL 11:00 OA20.01: Tumor Mutation Burden (TMB) is Associated 11:30 OA21.04: Discussant with Improved Efficacy of Atezolizumab in 1L and 2L+ Navneet Singh, Postgraduate Institute of Medical NSCLC Patients Education and Research (PGIMER), India Marcin Kowanetz, Genentech, Inc, USA 11:45 OA21.05: Wet M1a Non–Small Cell Lung Cancer: Is It Possible to Predict Recurrence of Pleural Effusion? 11:10 OA20.02: Neoantigen Targeting in NSCLC Patients with Riad Younes, Oncology Center Hospital Alemão Oswaldo Complete Response to Anti–PD–1 Immunotherapy Cruz, Brazil Kellie Smith, Johns Hopkins University School of Medicine, USA 11:55 OA21.06: Turning Best Supportive Care into Active Care. A Service Development for Patients with Advanced Lung 11:20 OA20.03: Tumoral IL–7 Receptor is a Potential Target for Cancer in NHS Fife, Scotland Lung Adenocarcinoma Immunotherapy Joanna Bowden, NHS Fife, UK Zachary Tano, Memorial Sloan Kettering Cancer Center, USA 12:05 OA21.07: Discussant Eva Masel, Medical University of Vienna, Austria 11:30 OA20.04: Discussant Wolfgang Hilbe, Austria 12:20 Q&A 11:45 OA20.05: The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non–Small Cell Lung Carcinomas Jaime Rodriguez–Canales, U.T.–M.D. Anderson Cancer Center, Translational Molecular Pathology, USA 11:55 OA20.06: Prospective ImmunogenomiC PrOfiling of 12:45 – 14:15 ISS12: Immuno–Oncology: Non–Small Cell Lung Cancer – The ICON Project A Renaissance in the Treatment Boris Sepesi, UT MD Anderson Cancer Center, USA of Lung Cancer – MSD Oncology 12:05 OA20.07: HHLA2, a New Immune Checkpoint Member TRACK: INDUSTRY SUPPORTED SYMPOSIUM of the B7 Family, is Widely Expressed in Human LungWEDNESDAY DECEMBER 7 Cancer and Associated with Mutational Status ROOM: LEHAR 3–4 Haiying Cheng, Albert Einstein College of Medicine/ Montefiore Medical Center, USA CHAIR: DAVID CARBONE, THE OHIO STATE WEXNER MEDICAL CENTER, USA 12:15 OA20.08: Discussant 12:45 ISS12.01: Welcome and Opening Remarks Helmut Popper, Medical University Graz, Austria David Carbone, The Ohio State Wexner Medical Center, USA 12:50 ISS12.02: Immunotherapy Experience in Lung Cancer Naiyer Rizvi, Columbia University Medical Center, USA 13:05 ISS12.03: The Value of Biomarkers in Lung Cancer Keith Kerr, Aberdeen University Medical School, UK 136 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION13:20 ISS12.04: Patient Management 15:25 OA22.07: Correlation of CT Scan Based Tumor Volume Thomas Newsom-Davis, Chelsea & Westminster Measurement to Actual Resected Tumor Volume – A Hospital, UK New T–Factor? Isabelle Opitz, University Hospital Zurich, Division of13:35 ISS12.05: Lung Cancer Landscape: Future Directions Thoracic Surgery, Switzerland David Carbone, The Ohio State Wexner Medical Center, USA 15:35 OA22.08: Discussant Viktoria Laszlo, Medical University Vienna, Austria13:50 ISS12.06: Panel Discussion – Faculty14:15 ISS12.07: Closing Remarks David Carbone, The Ohio State Wexner Medical Center, USA 14:20 – 15:50 OA23: EGFR Targeted Therapies in Advanced NSCLC14:20 – 15:50 OA22: Novel Trials and Biomarkers in Malignant Pleural Mesothelioma TRACK: ADVANCED NSCLC ROOM: STOLZ 2 TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ CHAIR: ODD TERJE BRUSTUGUN, NORWEGIAN RADIUM ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES HOSPITAL , NORWAY ROOM: STRAUSS 3 14:20 OA23.01: Anti–EGFR Monoclonal Antibodies plus Chemotherapy in the First–Line Treatment of Advanced CHAIRS: HARVEY PASS, NYU LANGONE MEDICAL CENTER, NSCLC: A Meta–Analysis USA & NICO VAN ZANDWIJK, UNIVERSITY OF SYDNEY, Gilberto Lopes, HCor Cancer Center, Brazil ASBESTOS DISEASES RESEARCH INSTITUTE, AUSTRALIA 14:30 OA23.02: Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR–14:20 OA22.01: STELLAR – Interim Results of a Phase 2 Trial of Expressing Tumors in SQUIRE, a Phase 3 Study TTFields with Chemotherapy for First Line Treatment of Tudor Ciuleanu, Institute of Oncology Ion Chiricuta and Malignant Mesothelioma UMF Iuliu Hatieganu, Romania Giovanni Ceresoli, Cliniche Humanitas Gavazzeni, Italy 14:40 OA23.03: Second–Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long–14:30 OA22.02: Nintedanib plus Pemetrexed/Cisplatin in Term Responders in the Phase III LUX–Lung 8 Trial Patients with Malignant Pleural Mesothelioma: Phase II Glenwood Goss, University of Ottawa, Canada Findings from the Placebo–Controlled LUME–Meso Trial Federica Grosso, SS Antonio e Biagio Hospital, Italy 14:50 OA23.04: Discussant Martin Sebastian, Goethe University, Germany14:40 OA22.03: HMGB1, a Target for Mesothelioma Therapy 15:05 OA23.05: First–Line Afatinib versus Gefitinib in and a Biomarker to Detect Asbestos Exposure and to EGFRm+ Advanced NSCLC: Updated Overall Survival Identify Mesothelioma Patients Analysis of LUX–Lung 7 Haining Yang, University of Hawaii Cancer Center, USA Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea14:50 OA22.04: Discussant Christian Rolfo, Antwerp University Hospital, Belgium 15:15 OA23.06: Overall Survival (OS) of EGFR Mutation Positive Non–Small Cell Lung Cancer Patients: Real–15:05 OA22.05: Breath Analysis by Gas Chromatography– World Treatment Patterns of 1,660 Japanese Patients WEDNESDAY DECEMBER 7 Mass Spectrometry Can Be Used to Screen for Pleural Kazushi Yoshida, National Cancer Center Hospital, Japan Mesothelioma Kevin Lamote, Ghent University, Belgium 15:25 OA23.07: Analysis of Outcomes in US IRESSA Clinical Access Program (ICAP) Patients on Gefitinib for More15:15 OA22.06: Refinement of the Prognostic miR–Score Than 10 Years for Use in Diagnostic Specimens from Chemo–Naïve Fred R. Hirsch, University of Colorado Cancer Center, Malignant Pleural Mesothelioma Patients USA Michaela Kirschner, University Hospital Zurich, Division of Thoracic Surgery, Switzerland 15:35 OA23.08: Discussant Melissa Johnson, Sarah Cannon Research Institute, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 137
14:38 MA15.04: Discussant Jürgen Fischer, Allergologie–Palliativmedizin– 14:20 – 15:50 OA24: Radiotherapy of Lung Cancer: Psychotherapie, Germany Recent Developments 14:50 MA15.05: PD–L1 Immunohistochemistry as Biomarker in TRACK: RADIOTHERAPY Non–Small Cell Lung Cancer (NSCLC) ROOM: STOLZ 1 Dagmar Krenbek, Otto Wagner Hospital, Department of CHAIR: KARIN DIECKMANN, MEDICAL UNIVERSITY OF Pathology, Austria VIENNA, AUSTRIA & STEFAN RIEKEN, GERMANY 14:20 OA24.01: Radiotherapy Quality Assurance of Concurrent 14:56 MA15.06: Predictive Value of Measuring Somatic Chemoradiotherapy in PROCLAIM Phase III Trial Mutations and Tumor Infiltrating Lymphocytes for PD–1 Anthony Brade, Trillium Health Partners, Canada Axis Therapy in Non–Small Cell Lung Cancer (NSCLC) Kurt Schalper, Yale University, USA 14:30 OA24.02: Locally Advanced Non–Small Cell Lung Cancer: 15:02 MA15.07: Molecular Determinants of Lack of Tumor RadioTherapy with Adaptive Strategy (LARTIA Trial) Immune Infiltration in NSCLC Sara Ramella, Campus Bio–Medico University, Italy Thomas Hensing, NorthShore University Health System, USA 14:40 OA24.03: Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose–Escalation Trials Delivering 70–90 Gy 15:08 MA15.08: Discussant Kyle Wang, University of North Carolina Hospitals, USA Izidor Kern, Slovenia 14:50 OA24.04: Discussant 15:20 MA15.09: Response to the Treatment Immediately Fiona McDonald, UK before Nivolumab Monotherapy May Predict Clinical Response to Nivolumab 15:05 OA24.05: The Nordic HILUS–Trial – First Report of a Haruki Kobayashi, Shizuoka Cancer Center, Japan Phase II Trial of SBRT of Centrally Located Lung Tumors Karin Lindberg, Karolinska Institutet, Sweden 15:26 MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD–1 Blockade 15:15 OA24.06: Histologic Subtype of Early–Stage Lung Immunotherapy in Lung Adenocarcinoma Adenocarcinoma is a Predictor of Failure Patterns after Zhong–Yi Dong, Guangdong Lung Cancer Institute, Stereotactic Body Radiation Therapy Guangdong General Hospital, China Abraham Wu, Memorial Sloan Kettering Cancer Center, USA 15:32 MA15.11: Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD–L1 Expression Status in Lung 15:25 OA24.07: The Impact of Population Heterogeneity on CancerK enichi Suda, University of Colorado Anschutz the Efficacy of SBRT to the Lung Medical Campus, USA Mohamed Abazeed, Cleveland Clinic, USA 15:38 MA15.12: Discussant 15:35 OA24.08: Discussant Martin Früh, Kantonsspital St. Gallen, Switzerland Feng-Ming (Spring) Kong, USA 14:20 – 15:50 MA15: Immunotherapy Prediction 14:20 – 15:50 MA16: Novel Strategies in Targeted Therapy TRACK: CHEMOTHERAPY/TARGETED THERAPY/ TRACK: CHEMOTHERAPY/TARGETED THERAPY/ IMMUNOTHERAPY IMMUNOTHERAPY ROOM: SCHUBERT 1, LEVEL ONE ROOM: STRAUSS 2 CHAIRS: MAYA GOTTFRIED, MEIR MEDICAL CENTER, ISRAEL CHAIRS: GUNTA PURKALNE, LATVIA & JOACHIM VON PAWEL, & OSCAR ARRIETA, MEXICO GERMANY 14:20 MA16.01: Targeted Gene Therapy for Tobacco Carcinogen–Induced Lung Cancer 14:20 MA15.01: Immunogram for Cancer–Immunity Cycle Nomundelger Gankhuyag, Seoul National University, towards Personalized Immunotherapy of Lung Cancer South KoreaWEDNESDAY DECEMBER 7 Takahiro Karasaki, Graduate School of Medicine, The University of Tokyo, Japan 14:26 MA16.02: Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas 14:26 MA15.02: Non–Synonymous Mutation Burden in Lung Katerina Politi, Yale University, USA Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade 14:32 MA16.03: Global RET Registry (GLORY): Activity of Navin Mahadevan, Brigham and Women’s Hospital, USA RET–Directed Targeted Therapies in RET–Rearranged Lung Cancers 14:32 MA15.03: The Predictive Value of Mutation/Neoantigen Oliver Gautschi, Lucerne Cantonal Hospital, Switzerland Burden from ctDNA on the Efficacy of PD–1 Blockade in Advanced NSCLC 14:38 MA16.04: Discussant Weijing Cai, Shanghai Pulmonary Hospital, China Myung–Ju Ahn, Samsung Medical Center, South Korea 138 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION14:50 MA16.05: For EGFR Mutant Non–Small Cell Lung Cancer, 14:26 MA17.02: Genome–Wide Copy Number and Mutational Treatment Sequence Matters? Analysis in Longitudinal B Ho Jung An, St. Vincent’s Hospital, The Catholic iopsies of Matched Primary and Metastatic Pulmonary University of Korea, South Korea Adenocarcinomas Thomas Lorber, Institute for Pathology, Switzerland14:56 MA16.06: Phase I/II Study of AC0010, Mutant–Selective EGFR Inhibitor, in Non–Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation 14:32 MA17.03: Identifying Genomic Alteration and Inter– Yi Long Wu, Guangdong Lung Cancer Institute, Tumor Heterogeneity of Multiple Primary Lung Cancers Guangdong General Hospital (GGH) and Guangdong by Targeted NGS of Tumor Tissue and ctDNA Academy of Medical Sciences, China Kezhong Chen, Peking University People’s Hospital, China15:02 MA16.07: Drug Repurposing to Overcome De Novo 14:38 MA17.04: Discussant Resistance of Non–Traditional EGFR Mutations József Tímár, Semmelweis University, Hungary Jacqulyne Robichaux, University of Texas MD Anderson Cancer Center, USA 14:50 MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung15:08 MA16.08: Discussant Adenocarcinomas Thanyanan Reungwetwattana, Ramathibodi Hospital, Hao–ran Zhai, Guangdong Lung Cancer Institute, Thailand Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China15:20 MA16.09: Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14–Altered Advanced Non– Small Cell Lung Cancer 14:56 MA17.06: Landscape of Somatic Mutations Involving Alex Drilon, Memorial Sloan Kettering Cancer Center, Lung Cancer Associated Genes in Non–Small Cell Lung USA Cancer (NSCLC) Patient–Derived Xenografts Vibha Raghavan, Princess Margaret Cancer Centre,15:26 MA16.10: Lung–MAP (S1400) Lung Master Protocol: Canada Accrual and Genomic Screening Updates Vassiliki Papadimitrakopoulou, MD Anderson Cancer 15:02 MA17.07: Circulating Tumor DNA Detects Minimal Center, USA Residual Disease and Predicts Outcome in Localized Lung Cancer 15:26 MA16.11: CNS Response to Osimertinib in Patients with Maximilian Diehn, Stanford University, USA T790M–Positive Advanced NSCLC: Pooled Data from Two Phase II Trials 15:08 MA17.08: Discussant Glenwood Goss, The Ottawa Hospital Cancer Centre, Leonhard Müllauer, Medical University Vienna, Austria University of Ottawa, Canada 15:20 MA17.09: Premature Fibroblast Senescence in Large Cell Carcinoma Provides Enhanced Growth and Invasive15:38 MA16.12: Discussant Advantages to Cancer Cells in Culture and in vivo Edgardo Santos, Lynn Cancer Institute, USA Marta Gabasa, Facultat de Medicina, Universitat de Barcelona, Spain 15:26 MA17.10: YES1 Kinase is a New Therapeutic Target in Non–small Cell Lung Cancer 14:20 – 15:50 MA17: Genetic Drivers Luis Montuenga, CIMA. University of Navarra, Spain TRACK: BIOLOGY/PATHOLOGY 15:32 MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis WEDNESDAY DECEMBER 7 ROOM: LEHAR 1–2 and Raf1 Overexpression Offsets This Effect in Non– CHAIRS: MIYAKO SATOUCHI, HYOGO CANCER CENTER, JAPAN Small Cell Lung Cancer Shuang Zhao, Department of Respiratory Medicine, GEORGE SIMON, MD ANDERSON CANCER CENTER, West China Hospital, Sichuan University, Chengdu USA 610041, China., China14:20 MA17.01: Microarray Identification of Genetic Drivers of Brain Metastasis in Lung Adenocarcinoma Gavitt Woodard, University of California, San Francisco, 15:38 MA17.12: Discussant USA Sanja Dacic, University of Pittsburgh, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 139
14:30 – 15:45 ED14: Small Cell Lung Cancer 14:30 – 15:45 SC30: Novel Approaches and Regulation in Surgical Education TRACK: SCLC/NEUROENDOCRINE TUMORS TRACK: SURGERY ROOM: HALL C2 ROOM: HALL C8 CHAIRS: DOMINIQUE GRUNENWALD, UNIVERSITY OF PARIS CHAIRS: JENS BENN SØRENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK & SABINE VI, FRANCE & YOUNG TAE KIM, SEOUL NATIONAL ZÖCHBAUER–MÜLLER, MEDICAL UNIVERSITY OF UNIVERSITY HOSPITAL, SOUTH KOREA VIENNA, AUSTRIA 14:30 ED14.01: Chemotherapy of Small Cell Lung Cancer 14:30 SC30.01: Robotic Surgery: The Future in Thoracic P rimo Lara, University of California Davis Surgery? Comprehensive Cancer Center, USA Housmanou Cheufou, Germany 14:45 ED14.02: Thoracic Radiotherapy of SCLC 14:50 SC30.02: Animal Models for Training of Thoracic B erend Slotman, VU University medical center, Surgeons Netherlands Young Tae Kim, Korea 15:00 ED14.03: Update on Prophylactic Cranial Irradiation in 15:10 SC30.03: E–Learning in Thoracic Oncology SCLC Jalal Assouad, Tenon Hospital Sorbonne University, Takashi Seto, National Kyushu Cancer Center, Japan France 15:15 ED14.04: Is There a Role for Surgery in SCLC? 15:30 SC30.04: Impact of Working Time Directives on Thoracic Georgios Stamatis, Ruhrlandklinik/University Essen, Surgical Training: The North–American Experience Germany Claude Deschamps, University of Vermont Medical Center, USA 15:30 ED14.05: Immunotherapy of Small Cell Lung Cancer Nevin Murray, British Columbia Cancer Agency, Canada 14:30 – 15:50 ED15: Thymic Malignancies: 14:30 – 15:45 SC31: Together Against Lung Cancer Update on Treatment – A Strategy for Success in the 21st Century TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ TRACK: SCIENTIFIC CO–OPERATION/RESEARCH GROUPS ESOPHAGEAL CANCER/OTHER THORACIC ROOM: HALL C7 MALIGNANCIES CHAIRS: MICHAEL BOYER, CHRIS O’BRIEN LIFEHOUSE, ROOM: HALL C1 AUSTRALIA & PIETER POSTMUS, INDEPENDENT, UK CHAIRS: HEATHER WAKELEE, STANFORD CANCER INSTITUTE, 14:30 SC31.01: The Role of Scientific Organizations USA & PAUL VAN SCHIL, ANTWERP UNIVERSITY Paul Bunn, Jr., University of Colorado Denver, USA HOSPITAL, BELGIUM 14:50 SC31.02: The Role of Patient Advocacy Groups B onnie Addario, Bonnie J. Addario Lung Cancer 14:30 ED15.01: Biology of Thymic Epithelial Tumors Foundation/ALCMI, USA Giuseppe Giaccone, Georgetown University, USA 14:50 ED15.02: Chemotherapy and Targeted Therapies of 15:10 SC31.03: The Role of Medical Journals Thymic Malignancies David Collingridge, The Lancet, UK N icolas Girard, Hospices Civils de Lyon, France 15:30 SC31.04: The Possibilities of Print & Social Media 15:10 ED15.03: Surgery of Thymic Malignancies Wolfgang Wagner, Austria Press Agency APA, Austria Meinoshin Okumura, Osaka Univeristy Graduate School of Medicine, Japan 15:30 ED15.04: Radiation of Thymic Malignancies Andreas Rimner, Memorial Sloan Kettering CancerWEDNESDAY DECEMBER 7 Center, USA 140 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION IA INTERACTIVE SESSION OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM PA PATIENT ADVOCACY SESSION WS WORKSHOP MA MINI ORAL ABSTRACT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION MTE MEET THE EXPERT SESSION (TICKETED) PL PLENARY SESSION14:30 – 15:45 NU05: Survivorship 14:30 – 15:45 Poster Presenters Present for TRACK: NURSES P3 Posters ROOM: SCHUBERT 5 CHAIRS: BETH IVIMEY, CHRIS O’BRIEN LIFEHOUSE, AUSTRALIA ROOM: HALL B (EXHIBIT HALL) & MARIA GUERIN, AINTREE UNIVERSITY HOSPITAL, P3.01 Biology/Pathology UK P3.02a Advanced NSCLC & Chemotherapy/Targeted Therapy/14:30 NU05.01: Use of Inspiratory Muscle Training in Immunotherapy Managing Dyspnoea in Lung Cancer Patients Andreas Charalambous, Cyprus University of P3.02b Advanced NSCLC & Chemotherapy/Targeted Therapy/ Technology, Cyprus Immunotherapy14:50 NU05.02: Comprehensive Long–Term Care of Lung P3.02c Advanced NSCLC & Chemotherapy/Targeted Therapy/ Cancer Patients: Development of a Novel Thoracic Immunotherapy Survivorship Program James Huang, Institution, USA P3.03 Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies15:10 NU05.03: What can we Learn from Other Tumor Sites About Survivorship P3.04 Surgery Natalie Doyle, The Royal Marsden NHS Foundation Trust, UK P3.05 Palliative Care/Ethics15:30 Q&A P3.06 Trial Design/Statistics P3.07 Regional Aspects/Health Policy/Public Health14:30 – 15:45 YI02: Basics of Radio–Oncology TRACK: RADIOTHERAPY ROOM: STRAUSS 1 CHAIRS: CORINNE FAIVRE–FINN, THE UNIVERSITY OF MANCHESTER AND THE CHRISTIE NHS FOUNDATION TRUST, UK & ROLF LEWENSOHN, KAROLINSKA UNIVERSITY HOSPITAL, SWEDEN14:30 YI02.01: PET–CT and MRI for Radiotherapy Planning of Lung Cancer U rsula Nestle, University Medical Center Freiburg, Germany14:50 YI02.02: Modern Treatment Techniques in Lung Cancer: The Advantages of Conformal Radiotherapy, IMRT and Proton Therapy WEDNESDAY DECEMBER 7 Satoshi Ishikura, Koshigaya Municipal Hospital, Japan15:10 YI02.03: Dose Limitations for Radiotherapy of Lung Cancer Antonio Juretic, School of Medicine, University of Zagreb and University Hospital Center “Zagreb”, Croatia15:30 YI02.04: Career Development in Radiation Oncology Laurie Gaspar, University of Colorado Denver Health Science Center, USA WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 141
ED EDUCATIONAL SESSION NU NURSES SESSION SC SCIENTIFIC SESSION ISS INDUSTRY SUPPORTED SYMPOSIUM OA ORAL ABSTRACT SESSION SH SCIENTIFIC HIGHLIGHT SESSION MA MINI ORAL ABSTRACT SESSION PA PATIENT ADVOCACY SESSION WS WORKSHOP MTE MEET THE EXPERT SESSION PC PRO CON SESSION YI YOUNG INVESTIGATOR SESSION (TICKETED) PL PLENARY SESSION 16:00 – 18:00 PL05: Closing Plenary Session: A Life in Thoracic Oncology – Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer ROOM: HALL D (PLENARY HALL) Thank you for attending. We look forward to seeing you in CHAIRS: PAUL BUNN, JR., UNIVERSITY OF COLORADO Yokohama in October 2017. DENVER, USA & TONY MOK, THE CHINESE UNIVERSITY OF HONG KONG, HONG KONG 16:00 PL05.01: Pathology Adi Gazdar, University of Texas Southwestern Medical Center, USA 16:15 PL05.02: Surgery Peter Goldstraw, National Heart and Lung Institute, Imperial College, UK 16:30 PL05.03: Radio–Oncology 16:45 David Ball, Peter MacCallum Cancer Centre, Australia DATE! 17:00 PL05.04: Translational Lung Cancer Research SAVE THENagahiro Saijo, Japanese Society of Medical Oncology, Japan OctoberPL05.05:Chemotherapy 15–18, 2017 | Yokohama, Japan Thierry Le Chevalier, Gustave Roussy Hospital, France 17:15 PL05.06: Targeted Therapy Frances Shepherd, Princess Margaret Cancer Centre, Canada 17:30 PL05.07: A Wise Man’s Conclusion Lawrence Einhorn, Indiana University, USA 17:45 PL05.08: Welcome to Yokohama for WCLC 2017 Hisao Asamura, Keio University School of Medicine, Japan & Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, South Korea 17:55 PL05.09: Farewell Robert Pirker, Medical University of Vienna, AustriaWEDNESDAY DECEMBER 7 Hisao Asamura, MD Professor and Chief Division of Thoracic Surgery Keio University School of Medicine Tokyo, JAPAN Keunchil Park, MD, Ph.D. Professor Division of Hematology/Oncology 142 IASLC 17TH WORLD CONFSEaRmENsuCEngONMLeUdNicGaClACNeCnEtRer| PROGRAM BOOK | WWW.IASLC.ORG Sungkyunkwan University School of Medicine Seoul, KOREA
SECTION 8Poster SessionsMonday, December 5 144Tuesday, December 6 166Wednesday, December 7 188 WEDNESDAY DECEMBER 7WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 143
MONDAY DECEMBER 5 / POSTERS AT A GLANCEMONDAY DECEMBER 5 P1.01 EPIDEMIOLOGY/TOBACCO CONTROL P1.05 EARLY STAGE NSCLC AND CESSATION/PREVENTION TRANSLATIONAL RESEARCH TOBACCO, RADON, AIR POLLUTION, P1.01–001 – P1.01–014 & BIOMARKERS P1.05–001 – P1.05–028 OTHER RISK FACTORS SBRT P1.05–029 – P1.05–035 SURGERY P1.05–036 – P1.05–044 PROTECTIVE FACTORS, RISK REDUCTION, NEOADJUVANT AND ADJUVANT CHEMOTHERAPY P1.05–045 – P1.05–054 SMOKING CESSATION P1.01–015 – P1.01–026 RECURRENCE P1.05–055 – P1.05–059 MISCELLANEOUS P1.05–060 – P1.05–079 LUNG CANCER SCREENING, DIAGNOSIS P1.01–027 – P1.01–034 PROGNOSTIC FACTORS, TREATMENT P1.01–035 – P1.01–051 DESCRIPTIVE EPIDEMIOLOGY P1.01–052 – P1.01–059 P1.02 BIOLOGY/PATHOLOGY DRIVER GENES IN NSCLC, P1.06 ADVANCED NSCLC & CHEMOTHERAPY/ RESISTANCE, AND OTHER TARGETED THERAPY/IMMUNOTHERAPY P1.02–001 – P1.02–061 OTHER MUTATIONS IN P1.02–062 – P1.02–086 ADVANCED GENERAL P1.06–001 – P1.06–045 THORACIC MALIGNANCIES ADVANCED ELDERLY P1.06–046 – P1.06–047 MISCELLANEOUS P1.02–087 P1.07 SCLC/NEUROENDOCRINE TUMORS P1.03 RADIOLOGY/STAGING/SCREENING BIOLOGY P1.03–001 – P1.03–007 DRUG TREATMENT ALONE AND P1.03–008 – P1.03–011 IN COMBINATION WITH RADIOTHERAPY P1.07–001 – P1.07–015 PNEUMONOLOGY P1.03–012 – P1.03–032 P1.03–033 – P1.03–064 LOCAL TREATMENT P1.07–016 – P1.07–022 RADIOLOGY P1.03–065 – P1.03–084 MOLECULAR CHANGES P1.07–023 – P1.07–035 SCREENING PATHOLOGY P1.07–036 – P1.07–039 STAGING PROGNOSTIC FACTORS P1.07–040 – P1.07–043 SCLC/NEUROENDOCRINE P1.07–044 – P1.07–055 TUMORS IN GENERAL P1.04 PULMONOLOGY PULMONOLOGY P1.04–001 – P1.04–028 P1.08 SURGERY RISK ASSESSMENT & P1.08–001 – P1.08–024 PROGNOSTIC FACTORS EPIDEMIOLOGIC STUDIES P1.08–025 – P1.08–031 IN SURGERY FOR NSCLC TRANSLATIONAL STUDIES P1.08–032 – P1.08–035 MINIMAL INVASIVE SURGERY P1.08–036 – P1.08–058 SURGERY FOR LOCALLY ADVANCED P1.08–059 – P1.08–083 AND ADVANCED NSCLC MISCELLANEOUS P1.08–084 144 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
MONDAY DECEMBER 5 / POSTERS IN DETAILPoster Setup Time: 08:30 – 10:15 P1.01–006: Interstitial Lung Diseases Are an Antecedent MONDAY DECEMBER 5Monday, December 5 of Lung Cancer Wonil Choi, Keimyung University School of Medicine, South KoreaPoster Takedown Time: P1.01–007: A Cross–Sectional Study on Tobacco ConsumptionMonday, December 5 15:45 – 18:00 Pattern among Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India(Posters not taken down by 18:00 will be discarded by management) Delfin Lovelina Francis, Tagore Dental College and Hospital, IndiaPoster Session with Presenters Present P1.01–008: Knowledge, Attitudes, and Smoking Behaviours(Presenting Author Stand By Time) Among Dental and Medical Students in Chennai, Tamil Nadu, India Delfin Lovelina Francis, Tagore Dental College and Hospital, IndiaSession in which Poster Presenters remains at his/her posterboard and is available to discuss/present their research P1.01–009: Smoking and Lung Cancer: Data from the Singlepersonally with interested delegates. Center in Albania Fatmir Caushi, University Hospital of Lung Diseases, AlbaniaMonday, December 5 10:25 - 11:00 P1.01–010: Awareness of Lung Cancer Risk Factors among Lay 14:30 – 15:45 Persons and Physicians Laurent Greillier, Hôpital Nord, France Hall B (Exhibit Hall) – Poster Area P1.01–011: Roflumilast Attenuates Benzo(a)Pyrene–InducedP1.01 EPIDEMIOLOGY/TOBACCO CONTROL Lung Cancer via Suppression of Airway Inflammation in Murine AND CESSATION/PREVENTION Model Chang Dong Yeo, Catholic University of Korea, South KoreaP1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION P1.01–012: Kava Effects on the Metabolism of Tobacco–Specific – TOBACCO, RADON, AIR POLLUTION, Carcinogen 4–(Methylnitrosamino)–1–(3–Pyridyl)–1–Butanone OTHER RISK FACTORS (NNK) in Humans Drew Oostra, University of Minnesota, USAP1.01–001: Reduction of Cigarette Consumption through aNational Policy for Tobacco Control in Brazil P1.01–013: Emphysematous Changes and Pulmonary FunctionAna Paula Teixeira, National Cancer Institute–Ministry of Health, for Asbestos–Related Lung Cancer in JapanBrazil Takumi Kishimoto, Okayama Rosai Hospital, JapanP1.01–002: Environmental Tobacco Smoke Exposure and EGFR P1.01–014: The Role of Hereditary Factor, Profession and theMutations/ALK Translocation in Never Smokers. A Multicentre Habit of Cigarette Smoking in Developing Lung CancerStudy in Spanish Never–Smokers Irina Pavlovska, Institute of Epidemiology and Biostatistics,Mónica Pérez–Ríos, University of Santiago de Compostela, Spain MacedoniaP1.01–003: Novel Associations between Lung Cancer–Related P1.01 EPIDEMIOLOGY/TOBACCO CONTROL ANDGenes and Indoor Radon Exposure CESSATION/PREVENTIONJung Ran Choi, Yonsei University Wonju College of Medicine, – PROTECTIVE FACTORS, RISK REDUCTION,South Korea SMOKING CESSATIONP1.01–004: Is There Any Role of Residential Radon in Non-Small Cell P1.01–015: Polyphenols–Rich Fruit Extracts Prevent TobaccoLung Cancer (NSCLC) Patients Harboring Molecular Alterations? Specific Nitrosamine–Induced DNA Damage in Lung Epithelial CellsLaura Mezquita, Gustave Roussy, France D.I.M. Amararathna, Dalhousie University, CanadaP1.01–005: First of Its Kind Study in India Finds That P1.01–016: An International Epidemiological Analysis of YoungGovernment’s Ban on Gutka (Highly Popular Smokeless Tobacco Patients Diagnosed with NSCLC (AduJov – CLICaP)Product) DID NOT Increase Smoking at All Luis Corrales–Rodriguez, CIMCA / Hospital San Juan de Dios,Gaurav Kumar, GMERS Medical College, India Costa Rica P1.01–017: The Dramatic Shift of Lung Cancer toward Young in Prisons Luc Renault, Hospices Civils de Lyon, Hôpital Lyon Sud, France WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 145
P1.01–018: Tobacco Use and Perceptions about Cessation P1.01–030: Factors Associated with Margin Positive Resections Training among Health Professions Students: Estimates by for Non–Small Cell Lung Cancer (NSCLC) in the Mid–South Countries and WHO Regions Region of the US Chandrashekhar Sreeramareddy, International Medical Matthew Smeltzer, University of Memphis School of Public University, Malaysia Health, USAMONDAY DECEMBER 5 P1.01–019: Integration of Tobacco Cessation Counseling in a Lung P1.01–031: Does Malignant Pleual Mesothelioma (MPM) Screening Program Behaviour Differ among Decades? Matthew Steliga, University of Arkansas for Medical Sciences, USA Fatma Abou Elkasem, National Cancer Insititute, Egypt P1.01–020: Chemopreventive Effect of Catechin Hydrates P1.01–032: Emergency Department Visits by Lung Cancer against Benzo(a)Pyrene Induced Lung Carcinogenesis in Mice: Patients in Korea Plausible Role of ALDH1 Dong Won Park, Hanyang University College of Medicine, South Ayaz Shahid, Jamia Hamdard University, India Korea P1.01–021: The Impact of Smoking Status on Overall Survival in a P1.01–033: EGFR Mutation and ALK: Are Patients Being Population–Based Non–Small Cell Lung Cancer (NSCLC) Surgical Adequately Tested in Brazil? Resection Cohort Gilberto Lopes, Núcleo de Oncologia da Bahia, Brazil Nicholas Faris, Baptist Cancer Center, USA P1.01–034: ECOG Scale of Performance Status in Lung Cancer P1.01–022: Smoking Cessation Related to Lung Resection at the First Consultation at a National Cancer Institute in a Tanel Laisaar, Tartu University, Estonia Developing Country in Latin America Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel P1.01–023: Smoking Cessation before Initiation of Riveros, Paraguay Chemotherapy in Metastatic Non–Small Lung Cancer: Influence on Prognosis P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal CESSATION/PREVENTION – PROGNOSTIC FACTORS, TREATMENT P1.01–024: University Students’ Perceptions about Effectiveness of MPOWER Policies on Tobacco Control in P1.01–035: Trends, Patterns of Treatment and Outcomes in Non– Panama City Panama Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Omar Castillo–Fernandez, Instituto Oncologico Nacional, Panama Cancer Data Base (NCDB) Analysis Madhusmita Behera, Winship Cancer Institute of Emory P1.01–025: Mass Media and Tobacco in Bangladesh: An University, USA Investigation on the Role of Mass Media in the Light of Tobacco Control P1.01–036: Lung Cancer Screening Program Is Cost Effective in Tahsina Sadeque, Somoy Television, Bangladesh French Setting: A Model Based Study Christos Chouaid, GRC OncoEst Creteil, France P1.01–026: Tobacco Use, Awareness and Cessation among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India Delfin Lovelina Francis, Tagore Dental College and Hospital, India P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND P1.01–037: Baseline Demographics and Comorbidities of CESSATION/PREVENTION Patients with Advanced NSCLC Compared to the General – LUNG CANCER SCREENING, DIAGNOSIS Population from Two Regions in Sweden Patrice Verpillat, Boehringer Ingelheim, Germany P1.01–027: Increased Risk of Lung Cancer among Women with Superficial TCC: A Potential Risk Cohort for Lung Cancer P1.01–038: Prognosis Value of Body Mass Index (BMI) and Screening Weight Loss at Diagnosis in Primary Lung Cancer: Results of Yaakov Tolwin, Tel Aviv University, Israel KBP–2010–CPHG Study Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud P1.01–028: High Risk Older Smokers’ Perceptions, Attitudes and Alsace (GHRMSA) – Hôpital Emile Muller, France Beliefs About Lung Cancer Screening Janine Cataldo, University of California, San Francisco, USA P1.01–039: Does Distance between Chest and Surgery Departments Impact Outcome in Lung Cancer Patients? Results P1.01–029: Personal and Hospital Factors Associated with of KBP–2010–CPHG Study Limited Surgical Resection, In–Hospital Mortality and Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud Complications in New York State Alsace (GHRMSA) – Hôpital Emile Muller, France Wil Lieberman–Cribbin, Icahn School of Medicine at Mount Sinai, USA P1.01–040: Long–Term Survival in Metastatic Non–Small–Cell Lung Cancer: An Investigation Using Surveillance, Epidemiology and End Results Data Eva Szabo, National Cancer Institute, USA P1.01–041: Quantitative Imaging Features Predict Response of Immunotherapy in Non–Small Cell Lung Cancer Patients Ilke Tunali, Namik Kemal University, Turkey 146 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
P1.01–042: Molecular Epidemiology of Programmed Cell Death P1.01–056: Lung Cancer Epidemiology in Croatia MONDAY DECEMBER 51–Ligand 1 (PD–L1) Protein Expression in Non–Small Cell Lung Robert Zorica, University Hospital “Split”, CroatiaCancerMatthew Schabath, H Lee Moffitt Cancer Center and Research P1.01–057: Metastatic Lung Cancer at a Tertiary Cancer Centre inInstitute, USA South India Govind Babu, Kidwai Memorial Institute Of Oncology, IndiaP1.01–043: Comparison of Gender, Race Distribution, andSurvival in the 1990s to 2010s in Lung Cancer Patients at a Single P1.01–058: Demographic Profile of Lung Cancer from Eastern IndiaInstitution Prasanta Mohapatra, All India Institute of Medical Sciences,Bahar Laderian, University of Miami, Miller School of Medicine, USA IndiaP1.01–044: Accelerometer–Determined Physical Activity and P1.01–059: Lung Cancer Epidemiology among the BahrainiSedentary Time among Lung Cancer Survivors Population, 2000–2011Adrijana D’Silva, University of Calgary, Canada Randah Hamadeh, Arabian Gulf University, BahrainP1.01–045: Patient to Hospital Distance in Access to Care and P1.02 BIOLOGY/PATHOLOGYLung Cancer Surgical TreatmentWil Lieberman–Cribbin, Icahn School of Medicine at Mount Sinai, P1.02 BIOLOGY/PATHOLOGYUSA – DRIVER GENES IN NSCLC, RESISTANCE, AND OTHERP1.01–046: Heterogeneity of NSCLC Surgery Exists in TreatmentPatterns and Hospital Costs among Different Centers of China, aStudy of 5060 PatientsJian Zhou, Peking University People’s Hospital, ChinaP1.01–047: Clinical Presentation and Outcome of Neuroendo- P1.02–001: Expressions of Resistance EGFR TKIs in Non Smallcrine Lung Tumors in a Brazilian Cohort from 2000 to 2016 Cell Lung CancerAt Pham Ngoc Thach Hospital – Viet NamMarcelo Corassa, A.C.Camargo Cancer Center, Brazil Nguyen Lam, Pham Ngoc Thach Hospital, VietnamP1.01–048: Factors Contributing Delays during Management of P1.02–002: Is T790M Mutation A “Regulator” for EGFR SignalLung Cancer: A Study from Tertiary Level Hospital in Nepal Pathway Not an Oncogene?Sandhya Acharya, National Academy Of Medical Sciences, Bir Zheng Wang, Beijing Hospital, ChinaHospital, Nepal P1.02–003: ROS1 (D4D6) is Reliable for ImmunohisochemistryP1.01–049: Predictors of High Grade Toxicity of Chemotherapy Detecting of ROS1 Fusion Lung Adenocarcinoma in Malignantamong Malignant Pleural Mesothelioma Patients Pleural EffusionFatma Abou Elkasem, National Cancer Insititute, Egypt Zheng Wang, Beijing Hospital, ChinaP1.01–050: Overall Survival in Advanced Lung Cancer Patients P1.02–004: A Retrospective Analysis of Frequency of ALK GeneTreated at Oncosalud–AUNA Rearrangement in Saudi Lung PatientsAlfredo Aguilar, Oncosalud – AUNA, Peru Fouad Al Dayel, King Faisal Specialist Hospital and Research Centre, Saudi ArabiaP1.01–051: Predictor Variables to ECOG Scale of PerformanceStatus in Lung Cancer at a Developing Country in Latin America P1.02–005: Frequency of Actionable Alterations in EGFR wtSilvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel NSCLC: Experience of the Wide Catchment Area of RomagnaRiveros, Paraguay (AVR) Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, ItalyP1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND P1.02–006: Interlaboratory Variation in Molecular Testing CESSATION/PREVENTION (EGFR, KRAS and ALK) in Stage IV Non–Squamous Non–Small – DESCRIPTIVE EPIDEMIOLOGY Cell Lung Cancer in the Netherlands in 2013 Chantal Kuijpers, University Medical Center Utrecht,P1.01–052: Lung Cancer Mortality in Mexico, 1990–2014 NetherlandsOscar Arrieta, Instituto Nacional de Cancerología, Mexico P1.02–007: Alk Translocated NSCLC in the West of Scotland:P1.01–053: Lung Cancer in Brazil: Men and Women Differences Patient Demographics and OutcomesMaria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil Nicola Steele, Beatson West of Scotland Cancer Centre, UKP1.01–054: Lung Cancer: Histology, Gender and Age Changes P1.02–008: 2–Year Single Institution Experience with EGFROver Past 30 Years in Brazil Plasma Testing in Advanced NSCLCMaria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil Izidor Kern, University Clinic of Respiratory and Allergic Diseases Golnik, SloveniaP1.01–055: Clinicoepidemiological Trends of Lung Cancer from aPremier Regional Cancer Centre in South IndiaAbhijit Das, Cancer Institute (WIA), India WWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER 147
MONDAY DECEMBER 5 P1.02–009: High Concordance of ALK Rearrangement Testing P1.02–022: Establishing Reflex NGS Testing in NSCLC in a between ALK RNA–In Situ Hybridization and IHC/FISH in Regional Network of County Hospitals in Central Sweden Patients with Lung Adenocarcinoma Johan Isaksson, Gävle Hospital, Sweden Akihiko Yoshizawa, Kyoto University Hospital, Japan P1.02–023: Application of an Amplicon–Based NGS Strategy in P1.02–010: Frequency of Uncommon EGFR Mutations in NSCLC the Molecular Diagnosis of NSCLC: Comparable Performance in an Argentinean University Institution with FISH and ARMS–PCR Carolina Gabay, Instituto de Oncología Angel H.Roffo, University Dongmei Lin, Peking University Cancer Hospital & Institute, China of Buenos Aires, Argentina P1.02–024: The Molecular Breakdown: A Comprehensive Look at P1.02–011: Comparison of EGFR and KRAS Mutations in Archival Non–Small–Cell Lung Cancer with ALK Rearrangement Tissue and Circulating Tumor DNA: The Impact of Tumor Ka–Won Noh, Sungkyunkwan University, South Korea Heterogeneity Ying Wang, BC Cancer Agency, Canada P1.02–025: Evaluation of NGS and RT–PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP P1.02–012: Frequencies of Actionable Mutations and Survival in Lungscape Project Variants of Invasive Adenocarcinoma of the Lung Stephen Finn, St James’s Hospital, Ireland Zhengbo Song, Zhejiang Cancer Hospital, China P1.02–026: Detection of Low–Abundant EGFR Somatic P1.02–013: Clinicopathological Characteristics and Survival of Mutations by PNA Clamping–Assisted Fluorescence Melting ALK, ROS1 and RET Arrangements in Non–Adenocarcinoma Non– Curve Analysis Small Cell Lung Cancer Patients Jihye Yoon, PANAGENE Inc., South Korea Zhengbo Song, Zhejiang Cancer Hospital, China P1.02–027: A Comparative Analysis of Different Cytological P1.02–014: HER2 Mutations in Chinese Patients with Non–Small Samples for the Assessment of ALK Gene Rearrangements in Cell Lung Cancer NSCLC Patients Zhengbo Song, Zhejiang Cancer Hospital, China Maria Lozano Escario, University of Navarra, Spain P1.02–015: A Multicenter Study of EGFR and EML4–ALK P1.02–028: Detection of Oncogenic Drivers in Pleural Effusions Detection in Non–Squamous, Non–Small–Cell Lung Cancer and Archived FNA Smears of Pulmonary Adenocarcinoma Patients with Malignant Pleural Effusion Deepali Jain, All India Institute of Medical Sciences, India Zhengbo Song, Zhejiang Cancer Hospital, China P1.02–029: Infrequent Staining Patterns in ALK P1.02–016: HER4 Expression Was Related to the Sensitivity of Immunohistochemistry: Correlation with Fish Analysis EGFR–TKI in Non–Small Cell Lung Cancer Paola De La Iglesia, Hospital Italiano de Buenos Aires, Argentina Masaaki Inoue, Shimonoseki City Hospital, Japan P1.02–030: Performance Evaluation of ALK/ROS1 Dual Break P1.02–017: Relative Abundance of EGFR Mutations Predict Apart FISH Probe Kit (RUO) in Non–Small–Cell Lung Cancer Tumor Metastasis and EGFR–TKIs Prognosis in Patients with Hyun Chang, Catholic Kwandong University International St. Non–Small Cell Lung Cancer Mary’s Hospital, South Korea Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China P1.02–031: Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes P1.02–018: Osteosarcomatous Differentiation in the Rebiopsy Paul Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Specimens of Patients Harboring Pulmonary Adenocarcinoma Medical School, USA with EGFR–TKI Resistance Hyun Jung Kwon, Seoul National University Bundang Hospital, P1.02–032: Diagnosis and Treatment of EGFR Mutated NSCLC South Korea among Arabic Patients Abed Agbaria, Bnay Zion Medical Center, Israel P1.02–019: Complex Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non–Small Lung Cancer P1.02–033: Mesenchymal Transformation is the Most Common Hiromasa Arai, Kanagawa Cardiovascular and Respiratory Center, Histomorphologic Changes in the Rebiopsy of Lung Cancer Japan Patients with EGFR–TKI Resistance Hyein Ahn, Seoul National University Bundang Hostpital, South P1.02–020: The Effect of EGF–Pathway Targeted Immunization Korea (EGF PTI) on STAT3 and Cancer Stem Cells in EGFR Mutant NSCLC Cells P1.02–034: EGFR Mutations and ALK Translocations in Lung Jordi Codony Servat, Pangaea Biotech SL, IOR Quirón–Dexeus Cancer – A National Study University Institute, Spain Erik Jakobsen, Odense University Hospital, Denmark P1.02–021: Review of Clinical Outcomes Attributable to Next P1.02–035: Concomitant Driver Mutation Determines Tumor Generation Sequencing Based Broad Mutation Panel Testing in Growth in EGFR Mutation–Positive Lung Adenocarcinoma Lung Adenocarcinoma Kazuhiro Nagayama, The University of Tokyo Hospital, Japan Cathal O’Brien, St James’s Hospital, Ireland 148 IASLC 17TH WORLD CONFERENCE ON LUNG CANCER | PROGRAM BOOK | WWW.IASLC.ORG
Search
Read the Text Version
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
